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Hypertension,	   or	   elevated	   blood	   pressure,	   is	   a	   very	   common	   risk	   factor	   for	  
cardiovascular	  disease	  and	  renal	  end	  organ	  damage.	  The	  prevalence	  of	  hypertension	  is	  28%	  
in	  the	  North	  American	  countries	  and	  44%	  in	  the	  European	  countries	  at	   the	  140/90	  mm	  Hg	  
threshold	  [1].	  Hypertension	  prevalence	   is	  strongly	  correlated	  with	  stroke	  mortality	   (r=0.78)	  
and	  more	   modestly	   with	   total	   cardiovascular	   disease	   (r=0.44)	   [1].	   In	   the	   vast	   majority	   of	  
cases,	  no	  specific	  cause	  can	  be	  identified,	  the	  so-­‐called	  essential	  hypertension.	  Accordingly,	  
treatment	   is	   symptomatic,	   by	   lifestyle	   intervention	  measures	   and	   antihypertensive	   drugs.	  
The	   lack	  of	  a	   causal	   intervention	   implies	   lifelong	   treatment	  associated	  with	  high	  costs	  and	  
burden	  for	  the	  patients.	  In	  a	  minority	  of	  the	  patients	  a	  specific	  cause	  can	  be	  identified,	  such	  
as	   primary	   aldosteronism,	   drug	   induced	  hypertension	   (such	   as	   due	   to	   oral	   contraceptives)	  
and	  sleep	  apnea	  syndrome;	  among	  these,	   renovascular	  hypertension	   is	   reported	   to	  be	   the	  
most	  frequently	  occurring	  [2,	  3],	  with	  prevalence	  between	  5%	  and	  20%	  in	  patients	  referred	  
for	  hypertension.	  
The	  concept	  of	  renal	  artery	  stenosis	  as	  a	  causal	  factor	  in	  hypertension	  derives	  from	  the	  
classical	  experiments	  by	  Harry	  Goldblatt	  in	  the	  1930s.	  [4-­‐7].	  He	  demonstrated	  that	  gross	  and	  
persistent	   elevation	   of	   blood	   pressure	   could	   be	   produced	   in	   dogs	   by	   clamping	   both	   renal	  
arteries	   or	   one	   if	   the	   other	   kidney	   had	   been	   removed.	   The	   hypertensive	   response	   to	  
disturbed	  blood	  flow	  to	  the	  kidneys	  has	  since	  been	  coined	  the	  Goldblatt	  phenomenon,	  and	  
provided	   the	  pathophysiological	  basis	   for	   the	  concept	  of	   renovascular	  hypertension.	  Many	  
clinical	   and	   epidemiological	   studies	   showed	   that	   renal	   artery	   stenosis	   was	   associated	   not	  
only	  with	  hypertension,	  but	  also	  with	  renal	  function	  loss	  and	  an	  increased	  mortality	  risk	   [8-­‐
13].	  	  Numerous	  studies	  aimed	  to	  elucidate	  the	  specific	  mechanisms	  underlying	  the	  Goldblatt	  
phenomenon	  [14,	  15]	  and	  its	  pathogenetic	  role	  in	  renovascular	  hypertension,	  on	  short	  and	  
long	  term	  and	  the	  general	  outline	  of	  the	  alleged	  pathogenesis	   is	  given	   in	  the	  figure	  on	  the	  








In	  the	  Goldblatt	  concept,	  briefly,	  the	  renal	  artery	  stenosis	  leads	  to	  a	  downstream	  decrease	  in	  
renal	  perfusion	  pressure	  that	  elicits	  a	  compensatory	  rise	  in	  activity	  of	  the	  renin-­‐angiotensin-­‐
aldosterone	   system	   (RAAS)	   with	   increased	   renin	   release	   from	   the	   downstream	   kidney,	   as	  
well	   as	   an	   increase	   in	   sympathetic	   nerve	   activity.	   Both	   lead	   to	   a	   rise	   in	   systemic	   blood	  
pressure	  that	  aims	  to	  restore	  renal	  perfusion	  pressure	  in	  a	  homeostatic	  feedback	  loop.	  The	  
elevated	  systemic	  blood	  pressure,	  however,	   cannot	   result	   in	   restoration	  of	   renal	  perfusion	  
pressure	   due	   to	   the	   presence	   of	   the	   renal	   artery	   stenosis,	   thus	   resulting	   in	   a	   persistently	  
elevated	  systemic	  blood	  pressure,	  that,	  on	   long	  term	  can	  result	   in	  hypertensive	  damage	  to	  
the	  systemic	  vascular	  bed	  and	  to	  target	  organs,	  i.e.	  the	  brain,	  the	  heart	  and	  the	  contralateral	  
kidney,	   that	   is	   not	   protected	   from	   the	   systemic	   hypertension	   by	   a	   stenotic	   artery.	   Renal	  
artery	   stenosis	   can	   occur	   due	   to	   atherosclerosis,	   which	   is	   usually	   generalized,	   and	   due	   to	  
fibromuscular	  dysplasia	  (FMD).	  Atherosclerotic	  renal	  artery	  stenosis	  (ARAS)	  is	  often	  found	  in	  
patients	   with	   extrarenal	   atherosclerosis	   (5-­‐40%),	   end-­‐stage	   renal	   failure	   (41%)	   and	   heart	  
failure	  (54%)	  [2],	  unlike	  FMD,	  which	  is	  a	  non-­‐inflammatory,	  non-­‐atherosclerotic	  disorder	  that	  
leads	  to	  arterial	  stenosis.	  Among	  patients	  with	  renovascular	  hypertension,	  FMD	  accounts	  for	  






As	  stated	  above,	  renovascular	  hypertension	  due	  to	  renal	  artery	  stenosis	  was	  reported	  
to	  be	  the	  most	  frequently	  occurring	  secondary	  form	  of	  hypertension	  [2,	  3].	  Not	  surprisingly,	  
much	  effort	  has	  been	  put	  into	  developing	  a	  causal	  treatment	  for	  renovascular	  hypertension,	  
thus	  pursuing	  normalization	  of	  blood	  pressure	  and	   its	  consequent	  cardiorenal	  risk,	  without	  
the	   burden	   of	   lifelong	   treatment.	   Studies	   focused	   on	   detection	   of	   renal	   artery	   stenosis	   in	  
patients	   referred	   for	   (treatment	   resistant)	   hypertension,	   verification	   of	   its	   pathogenetic	  
contribution	   to	   the	   elevated	   blood	   pressure	   and	   restoration	   of	   the	   patency	   of	   the	   renal	  
artery.	   Until	   today,	   the	   gold	   standard	   for	   diagnosing	   renal	   artery	   stenosis	   is	   renal	  
arteriography.	  A	   variety	   of	   less	   invasive	   tests	   have	  been	   evaluated	   for	   screening	   purposes	  
(duplex	   Doppler	   ultrasonography,	   magnetic	   resonance	   angiography	   and	   computed	  
tomographic	   angiography),	   but	   unfortunately	   false	   negative	   tests	   (low	   sensitivity)	   are	   the	  
major	   concern	   with	   all	   noninvasive	   tests.	   Functional	   tests	   like	   the	   captopril	   renal	  
scintigraphy,	  selective	  renal	  vein	  renin	  measurements,	  and	  plasma	  renin	  activity	  (in	  isolation	  
or	  after	  captopril	  administration)	  can	  support	  a	  functional	  role	  of	  the	  renal	  artery	  stenosis	  in	  
the	  elevated	  blood	  pressure,	  but	  are	  not	  useful	  as	  screening	  tests	  for	  renal	  artery	  stenosis.	  
Eventually,	   the	   choice	   of	   test	   should	   be	   based	   upon	   institutional	   expertise	   and	   patient	  
factors.	   If	   the	   noninvasive	   test	   is	   inconclusive,	   and	   the	   clinical	   suspicion	   remains	   high,	  
catheter	  angiography	  is	  recommended	  [18].	  
With	   the	   advancement	   of	   surgical	   techniques	   in	   the	   sixties	   and	   seventies	   of	   the	  
previous	   century,	   it	  became	  possible	   to	   reconstruct	   the	   renal	   artery	   to	   restore	   its	  patency	  
[19,	  20]	  as	  possible	  casual	   treatment	   for	   renovascular	  hypertension.	  However,	   renal	  artery	  
reconstruction	   requires	   major	   surgery,	   which	   was	   associated	   with	   a	   substantial	   mortality	  
rate	   (5.5%)	   especially	   in	   patients	   with	   diffuse	   atherosclerosis	   who	   also	   have	   heart	   failure	  
and/or	  moderate	   to	  advanced	   renal	   insufficiency	   [21,	  22].	   In	   the	  eighties	  and	  nineties	   this	  
was	  followed	  by	  percutaneous	  transluminal	  renal	  angioplasty	  (PTRA)	  and	  subsequently	  PTRA	  
with	   stenting	   of	   the	   renal	   artery	   stenosis	   [23-­‐26],	   both	   with	   the	   advantage	   of	   being	  
substantially	   less	   invasive	   than	   reconstructive	   vascular	   surgery.	   	   These	   procedures	   are	  
generally	  effective	  to	  improve	  patency	  of	  the	  renal	  artery,	  but	  had	  only	  variable	  success	  as	  to	  
improvement	  of	  hypertension	  and	  renal	  function	  [24]	  whereas	  data	  on	  long-­‐term	  mortality	  
have	   long	   been	   lacking.	   Increasing	   experience	   with	   patency	   restoration	   gradually	  
demonstrated	   that	   clinical	   benefit	   for	   blood	   pressure	   and	   sometimes	   renal	   function	   was	  








whereas	  for	  patients	  with	  ARAS	  the	  clinical	  benefits	  were	  much	  more	  variable	  [26].	  	  	  
The	  variability	  in	  clinical	  benefit	  of	  patency	  restoration	  raised	  the	  question	  whether	  the	  
effect	  of	  renal	  artery	  patency	  interventions	  on	  blood	  pressure	  and	  renal	  function	  in	  a	  given	  
individual	  with	  ARAS	  can	  be	  predicted	  from	  clinical	  parameters.	  In	  chapter	  2,	  therefore,	  we	  
review	   the	   past	   and	   current	   literature	   on	   atherosclerotic	   renovascular	   disease	   and	   renal	  
impairment	  as	  regards	  the	  question	  whether	  the	  effect	  of	  intervention	  aimed	  at	  restoration	  
of	  patency	  of	  the	  renal	  artery,	  as	  a	  possibly	  causal	  treatment,	  can	  be	  predicted.	  In	  chapter	  3	  
we	  examine	  the	  relationship	  between	  success	  of	  angioplasty	  on	  patency	  of	  the	  renal	  artery	  
on	   short	   term	   and	   during	   follow-­‐up,	   and	   the	   blood	   pressure	   response	   in	   a	   single	   center	  
cohort	  of	  patients	  with	  ARAS.	  	  
Next	   to	   the	   surgical	   and	   radiological	   treatment	   of	   renal	   artery	   stenosis	   aimed	   at	  
patency	   restoration,	   the	   development	   of	   drugs	   blocking	   the	   RAAS,	   such	   as	   angiotensin–
converting-­‐enzyme	   inhibitors	   (ACE-­‐i)	   followed	   by	   angiotensin-­‐II	   receptor	   blockers	   (ARB)	  
provided	  pharmacological	  strategies	  to	  ‘regulate	  and	  intervene’	  in	  the	  RAAS.	  Early	  after	  the	  
introduction	   of	   ACE-­‐i	   this	   was	   considered	   particularly	   suited	   for	   the	   treatment	   of	  
renovascular	   hypertension:	   after	   all,	   it	   was	   the	   RAAS	   that	   was	   held	   responsible	   for	   the	  
deleterious	  effect	  of	  renal	  artery	  stenosis	  on	  blood	  pressure.	  Whereas	  RAAS-­‐blockade	  turned	  
out	   to	   be	   a	   potent	   strategy	   for	   blood	   pressure	   reduction	   in	   severe	   hypertension,	  
nevertheless	  enthusiasm	   for	   its	  use	   in	   renovascular	  hypertension	  was	  curbed	  by	   two	  main	  
factors.	   First,	   the	   blood	   pressure	   response	   to	   ACE-­‐i	   in	   patients	   with	   renovascular	  
hypertension	   could	   vary	   from	   pronounced	   to	   absent.	   Moreover,	   RAAS-­‐blockade	   exerted	  
unwanted	  effects	  on	  renal	  function	  in	  some	  patients	  with	  renal	  artery	  stenosis.	  It	  turned	  out	  
that	  the	  intrarenal	  hemodynamic	  effects	  of	  ACE-­‐i	  can	  compromise	  renal	  function	  in	  a	  kidney	  
with	   low	  perfusion	  pressure,	  such	  as	   in	  a	  kidney	  behind	  a	   renal	  artery	  stenosis	   [27,	  28].	   In	  
line,	   acute	   renal	   failure	   can	   be	   a	   consequence	   of	   ACE-­‐i	   therapy	   in	   patients	   with	   bilateral	  
renal	  artery	  stenosis,	  or	  renal	  artery	  stenosis	  with	  a	  single	  functioning	  kidney.	  Nonetheless,	  
in	  patients	  with	  unilateral	  renal	  artery	  stenosis	  with	  normal	  kidney	  function,	  RAAS-­‐blockade	  
can	  be	  a	  valuable	  treatment.	  Chapter	  4	  describes	  the	  effect	  of	  monotherapy	  with	  an	  ACE-­‐i	  
(enalapril)	  or	  ARB	  (losartan)	  compared	  to	  dual	  blockade	  with	  combined	  therapy	  on	  the	  blood	  







Angiography	  is	  nowadays	  a	  frequent	  procedure	  for	  the	  detection	  of	  coronary	  as	  well	  as	  
peripheral	   arterial	   disease	   (PAD).	   Interestingly,	   ARAS	   is	   frequently	   encountered	   as	   an	  
incidental	   finding	   in	  patients	  undergoing	  routine	  angiography	  for	  PAD	  [2,	  29-­‐31]	  or	  routine	  
coronary	   angiography	   [2,	   32,	   33],	   with	   prevalences	   ranging	   from	   5	   to	   40%	   and	   from	   5	   to	  
20%,	  respectively.	  To	  date,	  the	   impact	  of	  renal	  artery	  stenosis	  as	  a	  risk	  factor	  for	  mortality	  
was	  established	  mainly	  in	  populations	  that	  underwent	  a	  diagnostic	  work-­‐up	  for	  hypertension	  
and/or	   renal	   failure,	   that	   is,	   on	   clinical	   suspicion	   of	   renovascular	   hypertension.	   The	  
prognostic	   impact	   of	   incidental	   renal	   artery	   stenosis,	   to	   the	   contrary,	   is	   unknown.	   To	  
examine	  the	  prognostic	   impact	  of	   incidental	  renal	  artery	  stenosis,	  we	  investigated	  a	  cohort	  
of	   patients	   with	   PAD	   (chapter	   5)	   who	   underwent	   intra-­‐arterial	   digital	   subtraction	  
angiography	   (DSA)	   by	   systematically	   reviewing	   the	   angiography	   data	   for	   incidental	   renal	  
artery	   stenosis,	   and	   analyzing	   for	   its	   possible	   association	   with	   prognosis.	   In	   patients	   with	  
PAD,	   mortality	   is	   high	   [34-­‐36]	   which	   is	   not	   surprising	   considering	   the	   clustering	   of	  
cardiovascular	   risk	   factors	   in	   these	  patients.	  Whether	   this	  mortality	   is	  due	   to	  an	   increased	  
(peri-­‐)	  operative	  risk	  related	  to	  the	  surgical	  vascular	  procedure	  or	  merely	  a	  representation	  of	  
the	  high-­‐risk	  profile	  of	  these	  patients	  is	  not	  known.	  For	  clinical	  purposes,	  however,	  it	  would	  
be	   very	   relevant	   to	   know	  whether	   incidental	   renal	   artery	   stenosis	   poses	   a	   specific	   risk	   for	  
patients	  in	  whom	  surgical	  vascular	  reconstruction	  is	  considered.	  In	  Chapter	  6,	  therefore,	  we	  
investigated	  the	  impact	  of	  incidental	  renal	  artery	  stenosis	  on	  long-­‐term	  mortality	  as	  well	  as	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Atherosclerotic	  renal	  artery	  stenosis	  (ARAS)	  is	  associated	  with	  hypertension,	  ischemic	  
nephropathy,	  and	  high	  cardiovascular	  risk.	  We	  review	  the	  data	  on	  revascularization	  of	  the	  
renal	  artery	  by	  percutaneous	  transluminal	   renal	  angioplasty	   (PTRA)	  and	  pharmacological	  
therapy.	   In	   patients	   with	   severe	   ARAS	   and	   poorly	   controlled	   hypertension,	   PTRA	   can	  
improve	   blood	   pressure	   control.	   In	   patients	   with	   rapid	   renal	   function	   loss	   and	   severe	  
ARAS,	  PTRA	  can	  improve	  short-­‐term	  renal	  function,	  but	  there	  is	  no	  evidence	  for	  long-­‐term	  
renoprotection.	  Recent	  evidence	  indicates	  that	  ARAS,	  and	  incidental	  renal	  artery	  stenosis,	  
considerably	  increases	  cardiovascular	  risk,	  independent	  of	  blood	  pressure,	  renal	  function,	  
and	  prevalent	  risk	  factors.	  This	  suggests	  that	  revascularization	  might	  potentially	   improve	  
overall	   prognosis,	   but	   no	   data	   are	   available	   currently.	   The	   high	   cardiovascular	   risk	  
warrants	  aggressive	  pharmacological	  treatment	  to	  prevent	  progression	  of	  the	  generalized	  
vascular	   disorder.	   Ongoing	   trials	   will	   show	   whether	   revascularization	   has	   added,	   long-­‐
term	  effects	  on	  blood	  pressure,	  renal	  function,	  and	  cardiovascular	  prognosis.	  
	  







	   Atherosclerotic	   renal	   artery	   stenosis	   is	   associated	   with	   hypertension,	   ischemic	  
nephropathy,	   cardiovascular	   disease	   [1,2],	   and	   a	   twofold	   to	   fivefold	   increase	   in	  
cardiovascular	  mortality	  [3–5].	  Furthermore,	  ARAS	  is	  assumed	  to	  account	  for	  5	  to	  15%	  [6],	  or	  
even	  25%	  of	  new	  cases	  of	  end-­‐stage	  renal	   failure	   [7].	  The	  exact	  prevalence	  of	  ARAS	   in	   the	  
general	   population	   is	   unknown	   because	   many	   cases	   remain	   undetected.	   In	   autopsies	  
conducted	  after	  stroke	  [8]	  and	  myocardial	  infarction	  [9],	  the	  prevalence	  of	  ARAS	  was	  10.4%	  
and	  12%,	   respectively.	   In	  a	   community-­‐based	  screening	   for	   cardiovascular	  disease	  and	   risk	  
factors	  from	  the	  United	  States,	  a	  prevalence	  of	  6.8%	  was	  reported	  in	  elderly	  patients	  with	  a	  
mean	  age	  of	  77	  years	  [10].	  Clinical	  studies	  report	  widely	  different	  prevalences	  in	  populations	  
with	  different	  clinical	  conditions.	  In	  hypertensive	  patients	  the	  prevalence	  of	  ARAS	  is	  less	  than	  
1%	  in	  unselected	  populations,	  whereas	  it	  is	  5%	  in	  hospital-­‐based	  populations,	  and	  up	  to	  40%	  
in	  third-­‐line	  referral	  clinics	  [11,12].	  Among	  patients	  starting	  dialysis,	  the	  prevalence	  of	  ARAS	  
was	   31%	   in	   women	   and	   22%	   in	   men	   [13].	   Finally,	   ARAS	   is	   frequently	   encountered	   as	   an	  
incidental	   finding	   in	   patients	   who	   undergo	   routine	   angiography	   for	   peripheral	   vascular	  
disease	  or	   coronary	  artery	  disease;	   in	   these	  populations	  prevalence	   ranges	   from	  5	   to	  40%	  
[14–17,18].	  	  
	   The	   treatment	   of	   ARAS	   has	   been	   a	   matter	   of	   dispute	   for	   a	   long	   time.	   In	   ARAS,	   as	  
opposed	   to	  FMD,	   the	  narrowing	  of	   the	   renal	  artery	   is	  not	  an	   isolated	  phenomenon,	  but	   is	  
part	   of	   a	   process	   of	   generalized	   atherosclerosis.	   The	   Goldblatt	   phenomenon,	   which	  
attributes	  the	  driving	  force	  of	  the	  pathophysiologic	  events	  to	  increased	  activity	  of	  the	  renin-­‐
angiotensin	   system	   due	   to	   perfusion	   impairment	   in	   the	   post-­‐stenotic	   kidney,	   may	   reflect	  
relatively	  well	  the	  pathophysiologic	  mechanisms	  in	  experimental	  models	  and	  in	  renal	  artery	  
stenosis	   (RAS)	   due	   to	   FMD,	   and	   is	   substantiated	   by	   the	   therapeutic	   benefits	   of	  
revascularization	  by	  PTRA	  or	  surgery	  in	  this	  condition	  [19].	  However,	  in	  ARAS	  the	  narrowing	  
of	   the	   renal	   artery	   is	   not	   an	   isolated	   phenomenon,	   but	   part	   of	   a	   progressive	   process	   of	  
generalized	  atherosclerosis.	  The	  impact	  of	  anatomical	  abnormalities	  in	  the	  renal	  artery	  as	  a	  
driving	   force	   in	   the	   elevated,	  multi-­‐organ	   cardiovascular	   risk	   in	   these	   patients,	   relative	   to	  
other	   mechanisms	   of	   end-­‐organ	   damage,	   is	   uncertain.	   It	   would	   seem	   logical	   to	   aim	   at	  
revascularization	  of	  the	  kidney,	  because	  this	  has	  the	  appeal	  of	  a	  causal	   intervention.	  Along	  







blood	   pressure	   and	   may	   prevent	   clinical	   events	   such	   as	   progressive	   renal	   failure	   [6].	  	  	  	  	  	  	  	  	  	  	  
The	  benefits	  and	  particularly	  the	  risks	  of	  intervention	  have	  not	  been	  well	  defined,	  however,	  
and	  prospective	  randomized	  data	  that	  also	  consider	  long-­‐term	  outcome	  are	  lacking.	  	  
	   On	   the	  other	  hand,	   there	   is	   increasing	  awareness	   that	  ARAS	  occurs	   in	   the	  context	  of	  
generalized	  atherosclerosis.	  Based	  on	  current	  guidelines	   for	  hypertension	   [20,21],	   the	  high	  
risk	  in	  patients	  with	  ARAS	  warrants	  aggressive	  treatment	  of	  the	  prevalent	  cardiovascular	  risk	  
factors	  (e.g.,	  hypertension,	  hypercholesterolemia,	  and	  glycaemia)	   in	  all	  patients	  with	  ARAS.	  
Possible	   benefits	   of	   revascularization	   thus	   should	   outweigh	   those	   of	   optimal	   conservative	  
intervention,	   and	   the	   possible	   benefit	   should	   be	   weighed	   against	   the	   risks	   of	  
revascularization	   for	   individual	   patients.	  However,	   it	   should	   also	  be	  noted	   that	   in	   patients	  
with	  ARAS,	   the	  risk	   for	  cardiovascular	  morbidity	  and	  mortality	   is	  greater	  than	  explained	  by	  
blood	  pressure	  alone	  [1]	  and,	  remarkably,	  the	  presence	  of	  RAS	  in	  itself	  is	  an	  independent	  risk	  
factor	  for	  cardiovascular	  morbidity	  and	  mortality	  [17,18].	  This	  raises	  the	  intriguing	  possibility	  
that	   revascularization	   may	   contribute	   to	   improvement	   of	   overall	   outcome	   in	   high-­‐risk	  
patients,	  even	  independent	  of	  blood	  pressure	  [18,22].	  
	   In	   this	   article	   we	   provide	   an	   overview	   of	   the	   available	   data	   on	   outcome	   of	  
revascularization	   on	   top	   of	   (optimal)	   pharmacological	   therapy	   in	   ARAS	   on	   blood	   pressure,	  
renal	  function,	  and	  prevention	  of	  cardiovascular	  events,	  and	  address	  the	  question	  whether	  
the	  therapeutic	  effect	  of	  revascularization	  can	  be	  predicted,	  in	  order	  to	  be	  able	  to	  select	  the	  
patients	  with	  ARAS	  who	  are	  likely	  to	  benefit	  from	  revascularization.	  	  
PTRA:	  Effects	  on	  Blood	  Pressure	  	  
	   Two	   types	   of	   revascularization	   procedures	   are	   available	   currently:	   PTRA	   with	   or	  
without	  stenting,	  and	  surgical	  reconstruction.	  PTRA	  is	  currently	  the	  first	  choice	  because	  it	  is	  
less	  invasive.	  Randomized	  data	  in	  patients	  with	  ostial	  ARAS	  showed	  that	  PTRA	  is	  as	  effective	  
as	  surgical	  reconstruction,	  and	  moreover,	  a	  simpler	  procedure	  [23].	  A	  recent	  meta-­‐analysis	  
of	  randomized	  controlled	  trials	  addressed	  the	  antihypertensive	  effect	  of	  balloon	  angioplasty	  
versus	   standard	   medical	   therapy	   in	   ARAS	   [24].	   The	   literature	   search	   identified	   three	  
published	   clinical	   randomized	   trials:	   the	   EMMA	   trial	   [25];	   the	   SNRASCG	   trial	   [26];	   and	   the	  
DRASTIC	  trial	   [27].	  Altogether	  there	  were	  210	  patients	   in	  the	  three	  trials	  with	  moderate	  to	  
severe	   (≥	   50%)	   unilateral	   or	   bilateral	   ARAS	   and	   poorly	   controlled	   hypertension	  who	  were	  
	  






followed	  for	  at	  least	  3	  months	  (longest	  follow-­‐up,	  12	  months)	  after	  intervention.	  The	  pooled	  
data	  using	  the	  3-­‐month	  follow-­‐up	  values	  from	  the	  DRASTIC	  trial	  and	  the	  6-­‐month	  data	  from	  
the	   two	   other	   trials	   showed	   a	   significantly	   greater	   decrease	   in	   both	   systolic	   and	   diastolic	  
blood	  pressure	   from	  baseline	   in	   the	  angioplasty	  group	  as	   compared	  with	  medical	   therapy.	  
The	  weighted	  mean	  difference	  between	  the	  two	  treatments	  was	  –7	  mm	  Hg	  (95%	  CI:	  –12	  to	  –
1	  mm	  Hg)	  for	  systolic	  blood	  pressure	  and	  –3	  mm	  Hg	  (95%	  CI:	  –6	  to	  –1	  mm	  Hg)	  for	  diastolic	  
blood	  pressure.	  Patients	  treated	  with	  balloon	  angioplasty	  (DRASTIC	  trial)	  were	  more	  likely	  to	  
have	  patent	  renal	  arteries	  after	  12	  months	  (52%	  vs	  19%;	  odds	  ratio	  =	  4.2;	  95%	  CI:	  1.8	  to	  9.8),	  
and	  had	  a	  significant	  decrease	  in	  median	  defined	  daily	  doses,	  in	  the	  EMMA	  trial	  at	  6	  months	  
(P	   =	   0.009)	   whereas	   in	   the	   DRASTIC	   trial	   at	   3	   months	   (P<	   0.001).	   The	   number	   of	  
antihypertensive	  drugs	  was	  also	  significantly	  lower	  in	  the	  balloon	  angioplasty	  group	  at	  both	  
3	  and	  12	  months	  in	  the	  DRASTIC	  trial.	  This	  allows	  us	  to	  conclude	  that	  balloon	  angioplasty	  on	  
top	   of	   standard	   medical	   therapy	   has	   a	   modest	   but	   significant	   effect	   on	   blood	   pressure	  
compared	  to	  medical	  therapy	  alone.	  Unfortunately,	  to	  date	  there	  are	  no	  randomized	  studies	  
comparing	  renal	  artery	  stenting	  to	  medication.	  
	   In	  a	  trial	  comparing	  PTRA	  plus	  stenting	  (PTRAS)	  to	  PTRA	  alone	  [28],	  PTRAS	  seemed	  to	  
be	  a	  better	  technique	  than	  PTRA	  to	  achieve	  vessel	  patency	  in	  ostial	  ARAS.	  However,	  the	  two	  
procedures	   did	   not	   differ	   in	   their	   effects	   on	   blood	   pressure	   outcome	   after	   6	   months	   of	  
follow-­‐up.	  
PTRA:	  Effects	  on	  Renal	  Function	  	  
	  	   The	   natural	   course	   of	   the	   rate	   of	   renal	   function	   decline	   in	   patients	   with	   ARAS	   is	  
uncertain.	  Progression	  of	  renal	   failure	   in	  patients	  with	  ARAS	  may	  reflect	  progression	   in	  the	  
degree	  of	  narrowing	  of	  the	  renal	  artery,	  progression	  associated	  with	  ischemic	  nephropathy,	  
or	  both.	  Rimmer	  and	  Gennari	  [6]	  reviewed	  five	  reports	  concerning	  serial	  angiograms	  in	  237	  
patients	  with	  ARAS.	  Progression,	  including	  worsening	  of	  existing	  stenosis	  of	  the	  renal	  artery	  
or	  the	  development	  of	  contralateral	  RAS,	  was	  reported	  in	  116	  patients	  (49%)	  during	  follow-­‐
up	  periods	  of	  6	  to	  18	  months.	  Renal	  artery	  occlusion	  occurred	  in	  28	  cases	  (14%).	  In	  another	  
report,	  the	  3-­‐year	  cumulative	  incidence	  of	  progression,	  defined	  as	  any	  detectable	  increase	  in	  
the	   degree	   of	   diameter	   reduction	   affecting	   at	   least	   one	   renal	   artery,	   was	   35%	   [29].	   In	   a	  







were	   a	   systolic	   blood	   pressure	   of	   at	   least	   160	  mm	   Hg,	   diabetes	   mellitus,	   and	   high-­‐grade	  	  	  	  	  	  	  
(≥	  60%	  stenosis,	  or	  occlusion)	  ipsilateral	  or	  contralateral	  stenosis	  [29].	  Thus	  far,	  the	  available	  
randomized	   controlled	   trials	   focused	   on	   the	   effect	   of	   PTRA	   (on	   top	   of	   medical	   therapy)	  
versus	   medical	   therapy	   alone	   on	   blood	   pressure	   [25–27].	   The	   EMMA,	   SNRASCG,	   and	  
DRASTIC	   studies	   are	   summarized	   in	   Table	   1.	   The	   studies	   separately	   did	   not	   show	  
improvement	  of	  renal	  function.	  	  
	  
	   Because	  the	  lack	  of	  effect	  might	  be	  due	  to	  the	  limited	  power	  of	  the	  separate	  studies,	  
due	   to	   their	   limited	   size	   and	   relatively	   short	   follow-­‐up,	   the	   previously	   mentioned	   meta-­‐
analysis	   [24]	   tried	   to	  combine	   the	   results	  of	   the	   three	  studies	   to	  see	  whether	   intervention	  
	  






could	   actually	   improve	   renal	   function	   outcome.	   However,	   because	   the	   effect	   on	   renal	  
function	  was	  measured	  in	  different	  ways,	  the	  results	  could	  not	  be	  pooled.	  	  
	   The	   fact	   that	   there	   was	   no	   improvement	   of	   renal	   function,	   despite	   anatomically	  
successful	  revascularization,	  may	  be	  explained	  in	  several	  ways.	  First,	  the	  patients	  included	  in	  
these	  studies	  all	  had	  relatively	  normal	  renal	   function	   (EMMA	  and	  DRASTIC	  studies)	  or	  only	  
mild	   renal	   insufficiency	   (SNRASCG	   study),	   so	   any	   improvement	   could	   be	   small	   as	  well	   and	  
thus	  difficult	  to	  detect.	  Second,	  the	  specific	  pathophysiology	  of	  renal	  function	  impairment	  in	  
ARAS	  should	  be	  taken	  into	  account.	  In	  unilateral	  ARAS,	  glomerular	  filtration	  rate	  (GFR)	  does	  
not	   reflect	   individual	   kidney	   function,	   because	   hyperfiltration	   in	   the	   normal	   kidney	   may	  
compensate	  for	  reduced	  filtration	  in	  the	  ischemic	  kidney.	  
Moreover,	  renal	  failure	  may	  result	  from	  both	  ischemia	  of	  the	  stenotic	  kidney,	  resulting	  
in	  progressive	  renal	  fibrosis	  and	  atrophy,	  and	  hypertensive	  nephropathy	  in	  the	  contralateral	  
kidney.	   In	   the	   stenotic	   kidney,	   both	   in	   unilateral	   and	   bilateral	   RAS,	   chronic	   ischemia	  may	  
eventually	   result	   in	   irreversible	   damage	   to	   the	   renal	   parenchyma,	   so	   that	   dilating	   the	  
stenotic	  lesion	  is	  no	  more	  than	  a	  “cosmetic”	  intervention.	  In	  this	  respect,	  La	  Batide-­‐Alanore	  
et	   al.	   [30]	   evaluated	   split	   renal	   function	   (SRF,	   estimated	   by	   technetium	   99mTc-­‐
diethylenetriamine	   penta-­‐acetic	   acid	   scintigraphy)	   outcome	   after	   PTRA	   in	   patients	   with	  
unilateral	  RAS	  (≥	  60%).	  They	  prospectively	  evaluated	  SRF	  and	  total	  GFR	  (clearance	  methods)	  
after	   successful	  PTRA	   in	  32	  consecutive	  hypertensive	  patients	  with	  RAS	   (18	  atherosclerotic	  
and	  14	  with	  dysplastic	  disease)	  and	  a	  total	  GFR	  of	  at	  least	  60	  mL/min	  per	  1.73	  m2.	  Six	  months	  
after	   successful	  PTRA,	   single-­‐kidney	  GFR	  of	   the	   stenotic	   kidney	  had	   increased	   significantly,	  
whereas	   concurrently	   single	   kidney	   GFR	   of	   the	   nonstenotic	   kidney	   decreased	   significantly	  
(Table	   1).	   Thus,	   reversal	   of	   both	   the	   hypoperfusion	   of	   the	   stenotic	   side	   and	   the	  
hyperperfusion	  of	  the	  nonstenotic	  side	  was	  observed,	  with	  a	  slight	  increase	  in	  total	  GFR	  as	  a	  
net	  result.	  This	  elegant	  study	  nicely	  demonstrates	  that	  “early”	  successful	  revascularization	  of	  
unilateral	  RAS	  (at	  least	  in	  patients	  with	  normal	  GFR)	  can	  facilitate	  restoration	  of	  the	  normal	  
distribution	  of	   renal	   blood	   flow,	   and	  hence	   renal	   function,	   between	   the	   two	   kidneys.	   This	  
presumably	  protects	   the	   stenotic	   kidney	   from	   ischemia,	   and	   the	   contralateral	   kidney	   from	  
hyperfiltration	   that	  may	   contribute	   to	   long-­‐term	   renal	   parenchymal	   damage,	   especially	   in	  
the	  presence	  of	  systemic	  hypertension.	  However,	  it	  should	  be	  emphasized	  that	  randomized	  







establishment	   of	   a	   new	   equilibrium	   after	   PTRA	   on	   prevention	   of	   further	   renal	   function	  
deterioration.	  
Although	  randomized	  studies	  are	  still	   lacking,	  several	  nonrandomized	  studies	  showed	  
improvement	  or	  even	  delay	  of	  dialysis	  after	  PTRA	  (with	  or	  without	  stenting)	  in	  patients	  with	  
ARAS	   and	   severe	   renal	   dysfunction	   (Table	   1).	   Beutler	   et	   al.	   [31]	   demonstrated	   that	   in	  
patients	  with	  pre-­‐stent	  declining	  renal	  function	  (an	  increase	  in	  serum	  creatinine	  of	  ≥	  20%	  in	  
12	  months),	  PTRAS	  improved	  median	  serum	  creatinine	  in	  the	  first	  1	  year	  (from	  2.02	  mg/dL	  
[1.5	   to	  3.0	  mg/dL]	   to	  1.71	  mg/dL	   [1.4	   to	  2.5	  mg/dL];	  P	  <	  0.05)	  and	  remained	  stable	  during	  
further	   follow-­‐up	   monitoring	   (12	   months	   after	   stent	   placement).	   The	   treatment	   had	   no	  
effect	  on	  serum	  creatinine	  levels	  if	  function	  had	  previously	  been	  stable.	  Similar	  results	  were	  
reported	   by	   Korsakas	   et	   al.	   [32]	   in	   28	   patients	  with	   a	   serum	   creatinine	   greater	   than	   3.33	  
mg/dL,	   and	  progressive	   loss	   of	   renal	   function	   at	   least	   1	   year	   before	   angioplasty,	   in	  whom	  
PTRA	   (with	   or	  without	   stent)	   slowed	   significantly	   progression	   of	   renal	   failure.	   A	   favorable	  
outcome	  was	   correlated	  with	  a	   lower	   creatinine	   level	   (P	   =	  0.0137)	   and	  a	  more	   rapid	  prior	  
loss	  of	  renal	  function	  (r	  =	  0.49,	  P	  =	  0.020)	  at	  entry.	  Roussos	  et	  al.	  [33]	  showed	  that	  patients	  
with	  ARAS	  who	  were	  referred	  for	  angioplasty	  because	  of	  deteriorating	  renal	  function	  (mean	  
serum	  creatinine:	  3.66	  ±	  1.89	  mg/dL)	  had	  a	  small	  increase	  in	  glomerular	  filtration	  rate	  at	  3-­‐
month	  follow-­‐up	  (from	  23	  ±	  11	  to	  27	  ±	  14	  mL/min/1.73	  m2;	  P	  =	  0.021).	  Analysis	  with	  patients	  
who	   had	   both	   renal	   function	   deterioration	   and	   accelerated	   hypertension	   showed	  
improvement	   of	   glomerular	   filtration	   rate	   (from	   25	   ±	   11	   to	   28	   ±	   14	  mL/min/1.73	  m2;	  P	   =	  
0.031)	  3	  months	  after	  intervention.	  However,	  no	  statistically	  significant	  difference	  was	  found	  
1	  year	  after	  angioplasty.	  	  
Several	   studies	   attempted	   to	   identify	   reliable	   predictors	   of	   renal	   function	   outcome	  
after	  revascularization.	  Halimi	  et	  al.	  [34]	  reported	  that	  the	  effect	  of	  intervention	  (PTRA,	  n	  =	  
5;	  or	  surgery,	  n	  =	  18)	  in	  a	  small	  heterogeneous	  group	  of	  ARAS	  patients	  was	  associated	  with	  
pre-­‐intervention	   albuminuria.	   On	   stepwise	   regression	   analysis,	   pre-­‐intervention	   urinary	  
albumin	  excretion	  was	  the	  only	  predictor	  of	  the	  response	  of	  renal	  function	  to	  intervention,	  
with	  lack	  of	  improvement	  in	  albuminuric	  patients.	  This	  suggests	  that,	  in	  ARAS,	  albuminuria	  is	  
a	  marker	  of	  intrarenal	  parenchymal	  damage	  that	  is	  not	  responsive	  to	  revascularization.	  This	  
is	   in	   accord	  with	   data	   reported	   by	   Campo	  et	   al.	   [35]	   in	   52	   patients,	   who	   reported	   better	  
outcome	  in	  renal	  function	  decline	  after	  PTRA	  in	  patients	  with	  proteinuria	  less	  than	  1	  g/day,	  
serum	   creatinine	   less	   than	   4	  mg/dL,	   and	   low	   resistance	   index,	   respectively.	   In	   this	   study,	  
	  






neither	   kidney	   size	   nor	   rapid	   prior	   renal	   function	   deterioration	   predicted	   outcome	   after	  
PTRA.	  A	  high	  resistance	  index,	  as	  assessed	  by	  Doppler	  ultrasonography,	  was	  also	  found	  to	  be	  
a	  predictor	  of	  worse	  outcome	  after	  PTRA	  for	  blood	  pressure	  and	  renal	  function	  in	  the	  study	  
by	   Radermacher	   et	   al.	   [36]	   in	   138	   ARAS	   patients.	   Unfortunately,	   however,	  many	   patients	  
with	   ARAS	   are	   obese	   and	   thus	   not	   easily	   accessible	   for	   reliable	   Doppler	   sonography;	  
moreover,	  the	  technique	  is	  relatively	  observer-­‐dependent.	  The	  finding	  of	  a	  small	  kidney	  size	  
(<	  8	  cm)	  is	  considered	  a	  sign	  of	  renal	  failure,	  and	  PTRA	  on	  such	  small	  kidneys	  should	  not	  be	  
undertaken,	  because	   it	   is	  unlikely	  that	  the	  risks	  outweigh	  the	  benefits—with	  the	  exception	  
of	  ARAS	  patients	  entering	  dialysis	  programs.	  Despite	  small-­‐sized	  (but	  not	  shrunken)	  kidneys,	  
several	  patients	  could	  discontinue	  dialysis	  after	  PTRA	  [37].	  Krijnen	  et	  al.	   [38]	  analyzed	  data	  
from	   the	   DRASTIC	   study,	   and	   found	   that	   patients	  with	   bilateral	   stenosis	   benefit	   the	  most	  
from	  immediate	  angioplasty	  with	  regard	  to	  renal	  function	  and	  blood	  pressure	  after	  1	  year	  of	  
follow-­‐up.	  	  
In	   summary,	  data	  on	   the	   impact	  of	  PTRA	  on	   renal	   function	  are	   relatively	   sparse,	  and	  
limited	  mainly	  to	  short-­‐term	  studies.	  Whereas	  apparently	  PTRA	  can	  favorably	  affect	  overall	  
renal	   function,	   such	  an	  effect	   is	  usually	  absent	   in	  patients	  with	  stable	   renal	   function,	  or	   in	  
those	   in	   whom	   irreversible	   parenchymal	   damage	   is	   present,	   as	   suggested	   by	   stable	  
moderate	   to	   severe	   renal	   function	   impairment	   or	   albuminuria.	   Current	   data	   indicate	   that	  
improvement	   of	   kidney	   function	   after	   renal	   vascularization	   (added	   to	   standard	   medical	  
therapy)	  may	  be	  expected	  in	  patients	  with	  rapid	  deterioration	  of	  renal	  function	  in	  the	  year	  
or	  months	   before	   intervention,	   in	  whom	   renal	   function	   is	   nevertheless	   still	   relatively	  well	  
preserved	  at	  the	  time	  of	  intervention.	  In	  selected	  cases,	  revascularization	  can	  result	  in	  renal	  
function	   improvement	   even	   in	   patients	   in	   whom	   rapid	   renal	   function	   deterioration	   is	   so	  
severe	   as	   to	   necessitate	   dialysis,	   as	   shown	   by	   case	   reports	   and	   Korsakas	   et	   al.	   [32].	   In	  
patients	   with	   normal	   to	   mildly	   impaired	   stable	   renal	   function,	   especially	   patients	   with	  
unilateral	   RAS,	   one	   cannot	   expect	   improvement	   of	   kidney	   function	   and	   the	   effect	   of	  
revascularization	  for	  the	  long-­‐term	  prognosis	  is	  uncertain.	  	  
PTRA:	  Effects	  on	  Prevention	  of	  Cardiovascular	  Events	  and	  Mortality	  
	   There	   are	   no	   randomized	   clinical	   trials	   evaluating	   the	   comparative	   effects	   of	   renal	  







patients	  with	  ARAS,	  with	  or	  without	   co-­‐morbid	   conditions	   [22].	   Yet,	   in	  patients	  with	  ARAS	  
the	  risk	   for	  premature	  cardiovascular	  death	  considerably	  exceeds	  their	   risk	   for	  progression	  
to	   end-­‐stage	   renal	   failure.	   The	   risk	   is	   particularly	   elevated	   in	   patients	  with	   lower	   baseline	  
renal	  function,	  which	  was	  reported	  to	  predict	  mortality	  after	  PTRA	  [39].	  	  
This	   elevated	   risk	  was	   demonstrated	   recently	   by	   Kalra	   et	   al.	   [1]	   in	   a	   large	   randomly	  
selected	   population	   cohort	   (n	   =	   1,085,250)	   and	   an	   essentially	   similar	   picture	   emerges	   for	  
patients	  with	   incidental	  RAS.	  Leertouwer	  et	  al.	   [15]	  showed	  that	  during	  10	  years	  of	   follow-­‐
up,	   if	   left	  untreated,	   incidental	  RAS	  did	  not	   lead	   to	  end-­‐stage	   renal	   failure	  or	   the	  need	   for	  
renal	   replacement	   therapy.	   Thus,	   revascularization	   is	   not	   recommended	   in	   incidentally	  
discovered	   RAS	   [14,15].	   However,	   the	   risk	   of	   cardiovascular	   mortality	   is	   considerably	  
increased,	   as	   demonstrated	   in	   a	   cohort	   of	   491	   patients	   with	   peripheral	   vascular	   disease,	  
where	   incidental	   RAS	   was	   associated	   with	   an	   increased	   prevalence	   of	   not	   only	   kidney	  
disease	   but	   also	   mortality	   (Fig.	   1)	   [18].	   Cox	   regression	   analysis	   showed	   that	   RAS	   was	   an	  
independent	  predictor	  of	  mortality	  (P	  =	  0.005),	  along	  with	  age,	  diabetes,	  smoking,	  previous	  
myocardial	  infarction,	  and	  stroke.	  Interestingly,	  inclusion	  of	  RAS	  in	  the	  multivariate	  analysis	  
abolished	   the	   effects	   of	   hypertension	   and	   renal	   function	   on	   mortality.	   Thus	   incidentally	  
found	  RAS	  is	  a	  marker	  of	  poor	  prognosis.	  This	  is	  partly	  explained	  by	  its	  close	  association	  with	  
extended	  cardiovascular	  disease,	  as	  well	  as	  with	  many	  established	  risk	  factors,	  such	  as	  older	  
age	   [18,40],	   impaired	   renal	   function	   [18],	   hypertension	   [18,41],	   history	   of	   coronary	   artery	  
disease	   [17,18,40]	   and	   diabetes	   [18,41].	   However,	   in	   the	   above	   population	  with	   PVD,	   the	  
increased	  risk	  for	  mortality	  could	  not	  be	  explained	  fully	  by	  these	  factors,	  which	  accords	  with	  
data	   from	  patients	  who	  undergo	  diagnostic	   cardiac	   catheterization	   simultaneously	  with	  an	  
aortography,	  in	  whom	  incidental	  RAS	  was	  an	  independent	  risk	  factor	  for	  mortality	  [17,42].	  	  
	   Moreover,	   the	   severity	   of	   RAS	   was	   related	   to	   mortality.	   Whether	   the	   independent	  
association	  between	  (incidental)	  ARAS	  and	  cardiovascular	  mortality	  implicates	  a	  causal	  effect	  
has	   not	   been	   established,	   but	   it	   is	   conceivable	   that	   neurohumoral	   activation	   from	   the	  
ischemic	  kidney	  exerts	  unfavorable	  cardiovascular	  effects.	   If	  so,	  revascularization	  may	  have	  
the	   potential	   to	   improve	   cardiovascular	   prognosis,	   even	   in	   incidental	   ARAS—as	   has	   been	  
suggested	   for	  heart	   failure	  patients	  with	  ARAS	   [22].	  Such	  studies,	  however,	  have	  not	  been	  
performed.	   At	   any	   rate,	   from	   the	   point	   of	   view	   of	   their	   high	   risk	   profile,	   all	   patients	  with	  
(incidental)	   ARAS	   should	   receive	   optimal	   pharmacological	   and	   supportive	   treatment	   to	  
manage	   their	   cardiovascular	   risk,	   in	   compliance	   with	   current	   guidelines.	   It	   is	   known	   that	  
	  






rigorous	  treatment	  of	  hypertension	  and	  strict	  regulation	  of	  diabetes	  improve	  cardiovascular	  
morbidity	   and	   mortality	   [43–45]	   and	   that	   an	   intensive	   (supra-­‐optimal)	   regimen	   of	   lipid-­‐
lowering	  statin	  drugs	  can	   improve	  prognosis	   in	  high-­‐risk	  populations,	  especially	   in	  patients	  
with	  coronary	  artery	  disease	  and	  metabolic	  syndrome	  [46,47].	  It	  would	  be	  of	  interest	  to	  test	  




	   Currently,	   four	   large	   randomized	   intervention	   trials	  are	  ongoing,	  with	  defined	  clinical	  
endpoints	  as	  summarized	  in	  Table	  2.	  The	  primary	  endpoint	  of	  the	  three	  ongoing	  trials	  from	  
Europe	   is	   the	   kidney	   function.	   The	   STAR	   trial	   aims	   to	   compare	   the	   effects	   of	   renal	   artery	  
stent	  placement	  together	  with	  optimal	  medication	  versus	  optimal	  medication	  alone	  on	  renal	  
function	  in	  ARAS	  patients	  [48].	  Patients	  are	  followed	  for	  2	  years	  with	  extended	  follow-­‐up	  to	  
5	   years.	   The	   primary	   outcome	   of	   this	   study	   is	   a	   reduction	   in	   creatinine	   clearance	   greater	  
than	  20%	  compared	  to	  baseline.	  This	  trial	  will	  include	  140	  patients.	  
	   	  
Figure	  1.	  Kaplan-­‐Meier	  survival	  
plots	   for	   491	   patients	   with	  
peripheral	   vascular	   disease,	  
comparing	   outcome	   for	   those	  
with	   incidentally	   discovered	  
renal	  artery	  stenosis	   (RAS)	  and	  
those	   without	   renal	   artery	  
stenosis	   (NRAS).	   On	   Cox	  
regression	   analysis	   the	  
elevated	   risk	   for	   mortality	   in	  
RAS	   was	   independent	   from	  
blood	   pressure,	   renal	   function	  









	   The	  NITER	  trial	  aims	  to	  evaluate	  whether	  medical	  therapy	  plus	  interventional	  PTRAS	  is	  
superior	   to	  medical	   therapy	   alone	  according	   to	   the	   following	   combined	  primary	   endpoint:	  
death	  or	  dialysis	   initiation	  or	   reduction	  by	  greater	   than	  20%	   in	  estimated	  GFR	  after	  0.5,	  1,	  
and	  2	  years	  of	   follow-­‐up	  and	  an	  extended	  follow-­‐up	  until	   the	  fourth	  year	   [49].	  The	  sample	  
size	  is	  estimated	  in	  50	  patients	  per	  group	  to	  achieve	  a	  statistical	  significance	  of	  0.05	  in	  case	  
of	  a	  reduction	  by	  50%	  in	  the	  combined	  endpoints.	  
The	  ASTRAL	  study	  is	  the	  largest	  trial,	  with	  the	  intention	  to	  include	  1000	  patients,	  and	  
compares	  angioplasty	   (with	  or	  without	  stenting,	  on	  top	  of	  medical	   therapy,	   free	  of	  choice)	  
with	  medical	   therapy	   (free	  of	  choice)	   [50].	  The	  progress	  of	  patients	  will	  be	   followed	   for	  at	  
least	  a	  year.	  The	  primary	  comparison	  is	  the	  rate	  of	  progression	  of	  renal	  failure,	  as	  assessed	  
by	  reciprocal	  creatinine	  plots	  over	  the	  course	  of	  the	  trial.	  Secondary	  endpoints	  include	  blood	  
pressure	   control	   and	   the	  occurrence	  of	   serious	  vascular	  events	   (e.g.,	  myocardial	   infarction	  
and	  stroke).	  
The	  latest	  trial	  is	  from	  the	  United	  States,	  the	  CORAL	  trial	  [51].	  Randomization	  will	  occur	  
in	  1080	  patients.	  Optimal	  medical	  therapy	  alone	  compared	  to	  stenting	  with	  optimal	  medical	  
therapy	   on	   a	   composite	   cardiovascular	   and	   renal	   endpoint	   (cardiovascular	   or	   renal	   death,	  
myocardial	  infarction,	  hospitalization	  for	  congestive	  heart	  failure,	  stroke,	  doubling	  of	  serum	  
creatinine,	  and	  need	  for	  renal	  replacement	  therapy)	  will	  be	  studied.	  Hopefully,	  these	  studies	  
have	  the	  potential	  to	  clarify	  the	  uncertainty	  concerning	  indications	  for,	  and	  outcomes	  after,	  
renal	  revascularization	  in	  patients	  with	  ARAS.	  
	  
	  







	   ARAS	   is	   a	   condition	   associated	  with	   hypertension,	   renal	   function	   impairment,	   and	   a	  
particularly	   high	   cardiovascular	   risk.	   This	   requires	   optimal	   medical	   therapy	   aimed	   at	  
treatment	  of	  the	  prevalent	  cardiac	  risk	  factors	  in	  all	  ARAS	  patients.	  Revascularization	  on	  top	  
of	  medical	   therapy	   can	   improve	   blood	   pressure	   control	   in	   patients	  with	   severe	   ARAS	   and	  
poorly	   controlled	   hypertension.	   Short-­‐term	   improvement	   in	   renal	   function	   has	   been	  
reported,	  but	  at	  this	  time	  there	  is	  no	  evidence	  that	  early	  revascularization	  can	  prevent	  long-­‐
term	   loss	  of	   renal	   function.	  However,	   in	   individuals	  with	   rapidly	  progressing	   renal	   function	  
loss	   and	   severe	   ARAS,	   PTRAS	   can	   improve	   renal	   function.	   Recent	   evidence	   indicates	   that	  
ARAS—and	   interestingly,	   incidental	   RAS—is	   associated	   with	   cardiovascular	   risk,	   also	  
independent	  from	  blood	  pressure,	  renal	  function,	  and	  prevalent	  cardiovascular	  risk	  factors.	  
This	  suggests	  that	  revascularization	  may	  have	  the	  potential	  to	  improve	  overall	  cardiovascular	  
prognosis.	   Ongoing	   randomized	   trials	   in	   ARAS	   address	   the	   long-­‐term	   effects	   of	  
revascularization,	  on	  top	  of	  pharmacological	  intervention,	  on	  blood	  pressure,	  renal	  function,	  
and	  mortality.	   It	   is	  hoped	   that	   these	   trials	  will	  provide	  us	  with	  data	   that	   can	  guide	  clinical	  
decision	  making	  in	  this	  grim	  condition.	  	  
Clinical	  Trial	  Acronyms	  
	   ASTRAL—Angioplasty	   and	   Stent	   for	   Renal	   Artery	   Lesions;	   CORAL—Cardiovascular	  
Outcomes	   in	   Renal	   Atherosclerotic	   Lesions;	   DRASTIC—Dutch	   Renal	   Artery	   Stenosis	  
Intervention	   Cooperative;	   EMMA—Essai	   Multicentrique	   Medicaments	   vs	   Angioplastie;	  
NITER—Nephropathy	   Ischemic	   Therapy;	   SNRASCG—Scottish	   and	   Newcastle	   Renal	   Artery	  
Stenosis	   Collaborative	   Group;	   STAR—Benefit	   of	   Stent	   Placement	   and	   Blood	   Pressure	   and	  
Lipid-­‐lowering	   for	   the	   Prevention	   of	   Progression	   of	   Renal	   Dysfunction	   Caused	   by	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  success	  of	  
angioplasty	  and	  blood	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patients	  with	  renal	  artery	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Recently,	   two	   randomized	   controlled	   trials	   showed	   no	   evidence	   of	   relevant	   clinical	  
benefit	   from	   revascularization	   in	  patients	  with	  atherosclerotic	   renal	   artery	   stenosis	   (ARAS)	  
[1,	   2].	   One	   possible	   explanation	   could	   be	   restenosis,	   but	   no	   data	   are	   available	   with	  
systematic	   angiographic	   follow-­‐up	   that	   allow	   to	   establish	   the	   association	   between	   blood	  
pressure	  effect	  and	  persistent	  patency	  of	  the	  vessel.	  	  Therefore	  we	  analyzed	  the	  radiological	  
and	  clinical	  data	  of	  a	  series	  of	  40	  patients	  with	  ARAS	  and	  hypertension,	  who	  underwent	  an	  
angioplasty	   (PTA)	   with	   protocolized	   repeat	   angiography	   after	   1	   year,	   irrespective	   of	   the	  
blood	  pressure	  response.	  	  
Forty	  patients,	  21	  women	  and	  19	  men,	  aged	  64	  ±	  6	  years	  were	  investigated	  for	  therapy	  
resistant	   and	   longstanding	   (7	   years)	   hypertension	   (>140/90	   mmHg	   on	   triple	   therapy	  
consisting	   of	   an	   ACE	   inhibitor,	   β-­‐blocker	   and	   a	   diuretic,	   or	   more)	   by	   means	   of	   an	   intra-­‐
arterial	   DSA.	   Renal	   artery	   stenosis	   was	   considered	   to	   be	   significant	   as	   a	   lumen	   diameter	  
reduction	  more	  than	  70%.	  In	  case	  of	  stenosis	  a	  PTA	  was	  performed.	  The	  patency	  of	  the	  renal	  
artery	   (<50%	   residual	   stenosis	   after	   angioplasty,	   measured	   with	   Dinavision,	   quantitative	  
angiography	   by	   Siemens,	   Netherlands)	   was	   re-­‐established	   after	   1	   year	   with	   angiography	  
(judged	   by	   a	   blinded	   radiologist,	   H.vdH).	   Blood	   pressure	   (BP)	   was	   measured	   by	   an	  
oscillometric	   device	   (Dinamap	   model	   8100,	   Critikon	   Inc.,	   Fla.,	   U.S.A.),	   during	   30	   minutes,	  
after	   1	   month	   (short-­‐term),	   and	   1	   year	   (long-­‐term)	   after	   PTA.	   The	   hypertension	   was	  
considered	  as	  improved	  when	  the	  SBP	  fell	  to	  140	  mmHg	  or	  less	  or	  DBP	  fell	  90	  mmHg	  or	  less	  
with	  the	  same	  or	  less	  medication.	  In	  a	  total	  of	  88	  renal	  arteries	  in	  40	  patients,	  there	  were	  60	  
renal	  artery	  stenoses.	  Twenty-­‐four	  patients	  had	  a	  unilateral	  stenosis	  (URAS)	  and	  16	  patients	  
had	  bilateral	  stenosis	  (BIRAS):	  of	  the	  latter	  seven	  stenoses	  had	  a	  diameter	  of	  less	  than	  3	  mm	  
and	   were	   not	   dilated.	   Before	   intervention	   mean	   BP	   was	   180	   ±	   24/98	   ±	   12	   mmHg	   in	   the	  
patients	   with	   URAS	   and	   178	   ±	   29/95	   ±	   17	   mmHg	   in	   the	   patients	   with	   BIRAS.	   PTA	   was	  
performed	   in	   53	   arteries:	   25	   in	   URAS	   and	   28	   in	   bilateral	   lesions.	   No	  major	   complications	  
occurred	  after	  PTA.	   Immediate	  patency	  was	  96%	   in	   the	  URAS	  group	   (1	   failure)	  and	  75%	   in	  
the	  BIRAS	  group	  (4	  failures).	  The	  long-­‐term	  patency	  overall	  was	  45%,	  with	  14	  restenoses	  in	  
the	  URAS	  and	  eight	   in	   the	  BIRAS	  group.	   In	  patients	   that	  developed	  restenosis	  after	  1	  year,	  	  	  	  
Δ	  BP	  from	  baseline	  was	  -­‐2	  ±	  27/1	  ±	  16	  and	  -­‐32	  ±	  56/-­‐4	  ±	  15,	  respectively,	  in	  URAS	  and	  BIRAS	  
group.	   In	  comparison,	  the	  Δ	  BP	   in	  patients	  with	  persistent	  patency	  was	   -­‐4	  ±	  30/-­‐10	  ±	  15	   in	  
URAS	  and	   -­‐7	  ±	  28/-­‐11	  ±	  18	   in	  BIRAS	  group	   (Table	  1).	  Neither	   in	  patients	  with	  URAS,	  nor	   in	  
Lack	  of	  relationship	  between	  success	  of	  angioplasty	  and	  blood	  pressure	  response	  in	  patients	  with	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patients	   with	   BIRAS,	   an	   association	   between	   BP	   response	   and	   patency	  was	   found	   after	   1	  
year	  (URAS:	  χ2	  =	  0.490,	  p	  =	  0.484	  and	  BIRAS:	  χ2	  =	  0.291,	  p=	  0.590,	  Table	  2).	  	  
	  
	  
Table	  1.	  Principal	  results	  of	  percutaneous	  transluminal	  angioplasty	  in	  ARAS	  patients	  
BIRAS,	   bilateral	   renal	   artery	   stenosis;	   PTA,	   percutaneous	   transluminal	   angioplasty;	   URAS,	   unilateral	   renal	   artery	  
stenosis.	  Stenosis	  defined	  as	  lumen	  reduction	  more	  than	  70%	  before	  PTA	  and	  patency	  defined	  as	  residual	  stenosis	  less	  
than	  50%	  after	  PTA.	  *P	  =	  NS	  versus	  baseline.	  
	  
Table	  2.	  Association	  patency	  after	  1	  year	  and	  blood	  pressure	  improvement	  
BP,	  blood	  pressure;	  PTA,	  percutaneous	  transluminal	  angioplasty.	  
	  
In	  this	  study	  there	  was	  no	  relationship	  between	  the	  patency	  success	  of	  angioplasty	  and	  
BP	  response	  at	  1	  year.	  Previous	  studies	  have	  shown	  restenosis	  in	  at	  least	  half	  of	  the	  patients	  
after	  6	  months	  [3],	  suggesting	  that	  restenosis	  accounts	  for	  the	  return	  of	  the	  hypertension.	  Of	  
note,	  repeat	  angiography	  is	  usually	  performed	  only	  when	  BP	  response	  is	  insufficient	  or	  when	  
BP	   rises	  again.	  Our	   study	   is	   the	   first	   to	   report	  on	  a	   cohort,	  albeit	   small,	  where	  all	  patients	  
underwent	  repeated	  angiography	  1	  year	  after	  angioplasty,	  irrespective	  of	  BP	  response,	  thus	  
avoiding	  bias	  by	  indication.	  In	  five	  of	  the	  patients	  in	  URAS	  with	  restenosis,	  BP	  was	  improved,	  
and	  in	  addition,	  in	  five	  of	  the	  patients	  with	  patent	  renal	  arteries,	  hypertension	  returned.	  At	  
variance	  with	  common	  belief,	   in	  our	  patients	  with	  URAS,	  the	  relationship	  between	  patency	  
of	   the	   renal	   artery	   and	   BP	   response	   is	   not	   one-­‐to-­‐one.	   For	   patients	   with	   BIRAS,	   the	  
association	  between	  BP	  response	  and	  patency	  is	  more	  ambiguous.	  In	  our	  group	  of	  patients	  
with	   BIRAS,	   there	   were	   seven	   stenoses	   not	   dilated	   because	   of	   the	   vessel	   size,	   so	   after	  
	  









(after	  1	  year)	  
Δ	  BP	  1-­‐year	  
systolic/diastolic	  	  
in	  mmHg	  
URAS	  (n=24)	   Yes:	  23	   -­‐2	  ±	  37/-­‐0	  ±	  13*	   Yes:	  10	   -­‐4	  ±	  30/-­‐10	  ±	  15*	  
	   No:	  1	   -­‐39/-­‐15	   No:	  14	   -­‐2	  ±	  27/1	  ±	  16	  
BIRAS	  (n=16)	   Yes:	  12	   -­‐8	  ±	  55/0	  ±	  21*	   Yes:	  8	   -­‐7	  ±	  28/-­‐11	  ±	  18*	  
	   No:	  4	   -­‐10	  ±	  50/3	  ±	  15	   No:	  8	   -­‐32	  ±	  56/-­‐4	  ±	  15	  
URAS	   PTA	  patent	   PTA	  not	  patent	   BIRAS	   PTA	  patent	   PTA	  not	  patent	  
BP	  improved	   5	   5	   	   5	   6	  






successful	  unilateral	  dilatation,	  the	  contralateral	  kidney	  was	  still	  underperfused,	  which	  may	  
have	  caused	  the	  hypertension.	  Furthermore,	  in	  bilateral	  lesions,	  either	  kidney	  (or	  both)	  can	  
be	  the	  driving	  force	  behind	  the	  hypertension,	  and	  it	  is	  impossible	  to	  determine	  which	  kidney	  
is	  the	  culprit	  without	  invasive	  biochemical	  measurements.	  So,	  the	  impact	  of	  restenosis	  on	  BP	  
cannot	   be	   assessed	   non-­‐invasively	   in	   presence	   of	   a	   contralateral	   stenosis.	   However,	   the	  
URAS	  data	  are	  clear-­‐cut,	  and	  our	  findings	  support	  the	  increasing	  body	  of	  evidence	  showing	  
that	  ARAS	  is	  not	  the	  main	  pathogenetic	  factor	  in	  the	  elevated	  blood	  pressure	  in	  the	  majority	  
of	  ARAS	  patients	  with	  hypertension.	  ARAS	  may	  be	  superimposed	  on	  essential	  hypertension,	  
and	   ARAS	   can	   also	   occur	   in	   the	   absence	   of	   hypertension,	   as	   suggested	   by	   studies	   in	  
peripheral	  arterial	  disease	  where	  incidental	  RAS	  was	  found	  in	  about	  25%	  of	  the	  patients	   [4,	  
5],	  of	  whom	  29%	  were	  normotensive.	  In	  many	  patients	  with	  ARAS	  renal	  arteriolosclerosis	  is	  
also	   present.	   The	   latter	   may	   be	   the	   main	   factor	   in	   renal	   ischemia,	   and	   can	   be	   the	  
perpetuating	   factor	   in	   hypertension	   despite	   alleviation	   of	   the	   ARAS.	   These	   factors	   may	  
explain	  the	  disappointing	  results	  of	  the	  STAR	  [1]	  and	  ASTRAL	  [2]	   in	  patients	  with	  ARAS	  and	  
kidney	   failure,	   which	   did	   not	   show	   any	   beneficial	   effect	   of	   stenting,	   on	   top	   of	   medical	  
therapy	  (also	  18%	  failure	  of	  the	  dilating	  procedures,	  and	  a	  moderate	  stenosis	  of	  50%).	  The	  
limitations	   of	   our	   study	   are	   the	   small	   number	   of	   patients	   and	   the	   post-­‐hoc	   design.	  
Additionally,	  we	  did	  not	  perform	  stenting,	  which	  may	  have	  affected	  patency	  during	  follow-­‐
up.	   In	   spite	   of	   these	   limitations,	   the	   prospectively	   planned	   repeated	   angiography	   in	   all	  
patients	  after	  1	  year	  provides	  unique	  data	  allowing	  to	  refute	  an	  association	  between	  success	  
of	  patency	  and	  blood	  pressure	  effect	  of	  anatomical	  intervention	  in	  ARAS.	  	  	  
In	  conclusion:	  we	  could	  not	  demonstrate	  any	  relationship	  between	  anatomical	  effects	  
on	  patency	  of	   the	   renal	  artery	  by	  PTA,	  and	   the	  BP	   response,	  or	   recurrence	  of	   the	  stenosis	  
and	  the	  return	  of	  hypertension.	  These	  data	  cast	  further	  doubt	  on	  the	  concept	  that	  ARAS	  play	  
a	  major	  role	  in	  causing	  so	  called	  renovascular	  hypertension.	  Other	  interventions,	  focusing	  on	  
treatment	   and	   prevention	   of	   small	   artery	   disease	   rather	   than	   dilating	   an	   incidental	   RAS,	  






Lack	  of	  relationship	  between	  success	  of	  angioplasty	  and	  blood	  pressure	  response	  in	  patients	  with	  renal	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Objective:	   To	   compare	   the	   effects	   of	   dual	   blockade	   with	   monotherapy	   angiotensin-­‐
converting-­‐enzyme	   inhibitor	   and	   angiotensin-­‐II	   receptor	   blocker	   in	   patients	   with	  
hypertension	  due	  to	  unilateral	  renal	  artery	  stenosis.	  	  
Design:	  An	  open	  label,	  prospective,	  randomized	  crossover	  study.	  	  
Setting:	   A	   single	   center	   study	   in	   a	   primary	   teaching	   hospital.	   Twelve	   patients	   with	  
angiographically	  proven	  unilateral	  renal	  artery	  stenosis	  and	  hypertension.	  	  
Intervention:	   In	   a	   crossover	   design,	   all	   patients	   were	   treated	   for	   three	   periods	   of	   eight	  
weeks.	  After	  a	  run-­‐in	  period,	  patients	  were	  randomized	  for	  either	  monotherapy	  enalapril	  or	  
losartan,	   followed	  by	   a	   second	   eight-­‐week	   period	   on	   the	   alternative	  monotherapy.	   At	   the	  
end	  of	  the	  second	  eight-­‐week	  period,	  dual	  therapy	  was	  given	  for	  eight	  weeks.	  	  
Results:	   The	   casual	   blood	   pressure	   on	   enalapril	  was	   180±9	   /92±4	  mm	  Hg	   and	   on	   losartan	  
180±9/97±6	   mmHg	   (both	   P	   <	   0.05	   compared	   to	   baseline).	   After	   dual	   therapy	   the	   blood	  
pressure	  was	  166±8/87±3	  mm	  Hg	  (P	  <	  0.01,	  for	  systolic	  BP,	  compared	  with	  baseline).	  The	  24-­‐
hour	   blood	   pressures	   decreased	   in	   the	   same	   magnitude:	   from	   166±9/88±4	   mmHg	   on	  
baseline,	   to	   155±12/86±6	   mmHg	   on	   enalapril,	   to	   159±9/81±5	   mmHg	   on	   losartan	   and	   to	  
148±8/83±3	  mmHg	  on	  dual	  therapy	  (P	  <	  0.05,	  compared	  to	  baseline).	  Serum	  creatinine	  and	  
potassium	  remained	  stable	  during	  all	  three-­‐treatment	  regimes.	  	  	  
Conclusion:	  Dual	   blockade	  of	   the	  RAAS	  by	   an	   angiotensin-­‐converting-­‐enzyme	   inhibitor	   and	  
angiotensin-­‐II	   receptor	   blocker	   was	   not	   superior	   compared	   to	   either	   monotherapy	   in	  
patients	  with	  renovascular	  hypertension.	  	  
 






Introduction	   	  
Atherosclerotic	   renal	   artery	   stenosis	   is	   the	   most	   common	   cause	   of	   secondary	  
hypertension,	  particular	  in	  older	  patients	  [1].	  Blood	  pressure	  control	  is	  important	  to	  prevent	  
both	  progressive	  target	  organ	  damage	  and	  progressive	  renal	  function	  loss	  in	  these	  patients	  
[2].	  Recent	  investigations	  have	  shown	  that	  revascularization	  procedures	  do	  not	  appear	  to	  be	  
superior	   to	   medication	   in	   patients	   with	   renal	   artery	   stenosis	   [3,	   4].	   Therefore,	  
pharmacological	  treatment	  plays	  a	  central	  role	   in	  blood	  pressure	  control	   in	  this	  population	  
[5-­‐8].	   Angiotensin-­‐converting-­‐enzyme	   inhibitors	   effectively	   lower	   blood	   pressure	   in	  
renovascular	   hypertension,	   but	   in	   many	   patients	   monotherapy	   is	   not	   sufficient	   to	   obtain	  
normal	   blood	   pressure	   [9].	   Several	   data	   have	   shown	   that	   dual	   blockade	   of	   the	   renin-­‐
angiotensin-­‐aldosterone	   system	   (RAAS)	   by	   combined	   ACE-­‐i	   and	   angiotensin-­‐II-­‐	   receptor	  
blocker	   is	  more	   effective	   than	   either	  monotherapy	   in	   these	   patient	   categories	   [10-­‐14].	   So	  
far,	   no	   studies	   addressed	   this	   issue	   in	   patients	   with	   ARAS,	   a	   condition	   that	   is	   frequently	  
associated	   with	   resistance	   to	   antihypertensive	   therapy.	   Therefore,	   we	   studied	   the	   blood	  
pressure	   response	  with	  monotherapy	   enalapril	   and	   losartan,	   respectively,	   in	   a	   short	   term,	  
crossover	   study	   in	   a	   small	   group	   of	   patients	   with	   unilateral	   renal	   artery	   stenosis,	   as	  
compared	  to	  the	  effect	  of	  combined	  blockade	  of	  both	  drugs.	  	  
	  
Patients	  and	  Methods	  
Fifteen	   patients,	   nine	   male	   and	   six	   female	   (mean	   age	   65	   ±	   8	   yr)	   with	   renovascular	  
hypertension	   due	   to	   URAS	   were	   recruited	   from	   the	   outpatient	   clinic	   of	   the	   Twenteborg	  
Hospital	   Almelo.	   Renovascular	   hypertension	   was	   diagnosed	   based	   on	   angiographically	  
proven	  URAS	  with	  more	  than	  50%	  lumen	  reduction	  and/or	  an	  abnormal	  renal	  scintigraphy	  of	  
the	  affected	  side.	  Hypertension	  was	  defined	  as	  a	  casual	  diastolic	  blood	  pressure	  greater	  than	  
95	   mm	   Hg	   on	   two	   occasions	   in	   the	   run-­‐in	   period.	   Before	   the	   trial,	   all	   patients	   had	   well-­‐
controlled	  blood	  pressures	  using	  ACE-­‐i,	   ten	  patients	  also	  used	  diuretics	  and	   seven	  patients	  
had	  at	  least	  triple	  therapy	  including	  a	  Beta-­‐blocker.	  Exclusion	  criteria	  were	  severe	  cardiac	  or	  
cerebrovascular	  disease	  and	  malignant	  hypertension.	  Serum	  creatinine	  had	  to	  be	  stable	  and	  
below	  150	   µmol/l	   for	   at	   least	   6	  months.	  Written	   informed	   consent	  was	   obtained	   from	  all	  








The	   study	   was	   conducted	   according	   to	   an	   open	   label,	   prospective,	   crossover	   study	  
design.	   All	   previous	   antihypertensive	  medications	   were	   withdrawn	   for	   at	   least	   one	   week.	  
After	  discontinuation	  of	  medication,	  patients	  visited	  the	  outpatient	  clinic	  twice	  a	  week.	  For	  
safety	  reasons,	  patients	  were	  allowed	  to	  start	  with	  the	  study	  medication	  when	  the	  diastolic	  
blood	  pressure	  exceeded	  115	  mmHg.	  Median	  period	  without	  medication	  was	  10	  ±	  3	  days.	  
After	  the	  baseline	  period,	  patients	  were	  randomized	  to	  start	  with	  monotherapy	  enalapril	  20	  
mg	  bid	  or	   losartan	  50	  mg	  bid,	   for	  eight	  weeks	   followed	  by	  eight	  weeks	  on	   the	  other	  drug.	  
After	   the	  2	  periods	  of	  8	  weeks	  monotherapy,	   all	   the	  patients	   received	   the	   combination	  of	  
losartan	  and	  enalapril	  for	  8	  weeks	  in	  the	  same	  dosage.	  Patients	  visited	  the	  outpatient	  clinic	  
at	   4	   weeks	   intervals,	   for	   measurement	   of	   blood	   pressure	   and	   laboratory	   measurements.	  
Twenty-­‐four	  hour	  blood	  pressure	  measurements	  were	  made	  at	  baseline	  and	  at	   the	  end	  of	  




Casual	  blood	  pressure	  was	  measured	  with	  a	  standard	  sphygmomanometer.	  The	  patients	  
were	   required	   to	   remain	   in	   a	   sitting	   position	   for	   at	   least	   five	   minutes,	   after	   which	   three	  
consecutive	   blood	   pressure	  measurements	   separated	   by	   one	  minute	  were	  made.	   Twenty-­‐
four	   hour	   blood	   pressure	   measurements	   were	   done	   with	   a	   Spacelabs	   90207	   device	  
(Spacelabs,	   Ohio,	   USA).	   Measurements	   included	   twenty-­‐four	   hour	   mean,	   diastolic	   and	  
systolic	  blood	  pressure,	  daytime	  values	  (measured	  every	  15	  min	  from	  7.00	  to	  22.00	  h)	  and	  
nighttime	  values	  (measured	  every	  20	  min	  from	  22.00	  to	  7.00	  h).	   If	   the	  number	  of	  readings	  
was	  more	  than	  80%,	  the	  measurement	  was	  noted	  as	  successful.	  
Renal	  function	  and	  serum	  electrolytes	  
Serum	  BUN,	  creatinine	  and	  electrolytes	  (potassium	  and	  sodium)	  were	  measured	  every	  four	  
weeks	  and	  renal	  function	  was	  estimated	  by	  the	  Cockcroft	  formula	  [15].	  
	  
Data	  analysis	  
Data	   are	   given	   as	   means	   and	   standard	   errors	   of	   the	   mean.	   Comparison	   of	   blood	  
pressures	  and	  renal	   function	  were	  assessed	  using	  ANOVA	  test	   for	   repeated	  measurements	  
(using	   SPSS	   11.1	   software,	   Gorinchem,	   the	   Netherlands).	   Correlation	   between	   individual	  
 






responses	   was	   calculated	   by	   means	   of	   Spearman	   rank	   test.	   A	   P	   value	   of	   <	   0,05	   was	  
considered	  statistically	  significant.	  	  	  	  	  
	  
Results	  
Three	  patients	  did	  not	  complete	  the	  trial	   (2	  due	  to	  angina	  pectoris	  after	  withdrawal	  of	  
their	  Beta	  blocker,	  and	  1	  patient	  developed	  a	  lung	  carcinoma	  in	  the	  first	  treatment	  period),	  
the	  remaining	  12	  patients	  were	  able	  to	  complete	  the	  trial.	  Three	  patients	  refused	  to	  undergo	  
24-­‐hour	  blood	  pressure	  measurements,	  so	   in	  9	  patients	  results	   for	  the	  24-­‐hour	  BP	  analysis	  
were	  available.	  Group	  means	  are	  depicted	   in	  table	  1.	  After	  discontinuation	  of	  the	  previous	  
medication	   the	   casual	   blood	   pressure	   rose	   from	   154±10/	   89±4	   to	   201±10/	   105±5	   mmHg	  
(P<0.001).	  After	  8	  weeks	  treatment	  with	  enalapril	  blood	  pressure	  decreased	  to	  180±9/	  92±4	  
mmHg	   and	   after	   8	   weeks	   losartan	   to	   180±9/	   97±6	   mmHg.	   Combination	   therapy	   further	  
decreased	   blood	   pressure	   to	   166±8/	   87±3	   mmHg	   (P<	   0.05,	   compared	   with	   enalapril	   and	  
losartan).	  Measurements	  of	   the	  24-­‐hour	  blood	  pressures	  showed	  a	  similar	  pattern,	   though	  
the	  absolute	  values	  were	  lower.	  None	  of	  the	  measured	  blood	  pressures	  differed	  significantly,	  
though	  a	  tendency	  for	  further	  lowering	  on	  combination	  therapy	  was	  noted	  (Table	  1).	  Renal	  
function	   remained	   stable	   under	   the	   three	   treatment	   modalities	   (Table	   1)	   and	   serum	  
potassium	  did	  not	  increase	  during	  dual	  blockade.	  	  
	  
Table	  1.	  Effects	  of	  treatment	  with	  enalapril,	  losartan	  and	  combination	  therapy	  on	  casual	  blood	  pressure,	  
24-­‐hour	  blood	  pressure	  (n=9)	  and	  Cockcroft	  clearance	  in	  12	  patients	  with	  renovascular	  hypertension.	  	  
	   Previous	  
therapy	  
Base	  line	   Enalapril	   Losartan	   Combination	  
therapy	  
24	  hour	  ABPM	   	   	   	   	   	  
-­‐	  Systolic	  BP	  (mmHg)	   	   166	  ±	  9	   155	  ±	  12	   159	  ±	  9	   148	  ±	  8a	  
-­‐	  Diastolic	  BP	  (mmHg)	   	   88	  ±	  4	   86	  ±	  6	   81	  ±	  5	   83	  ±	  3	  
Mean	  BP	  (mmHg)	   	   115	  ±	  5	   110	  ±	  7	   109	  ±	  5	   107	  ±	  5	  
Casual	  BP	   	   	   	   	   	  
-­‐	  Systolic	  BP	  (mmHg)	   154	  ±	  10c	   201	  ±	  10	   180	  ±	  9a	   180	  ±	  9a	   166	  ±	  8a,b	  
-­‐	  Diastolic	  BP	  (mmHg)	   89	  ±	  4c	   105	  ±	  5	   92	  ±	  4a	   97	  ±	  6a	   87	  ±	  3a	  
Creat	  Cl	  (ml/min)	   	   72	  ±	  6	   72	  ±	  6	   74	  ±	  5	   70	  ±	  6	  
	  
ABPM,	   24-­‐hour	   ambulatory	   blood	   pressure;	   BP,	   blood	   pressure;	   Creat	   Cl,	   Cockcroft	   clearance.	   a	   =	   p	   <	   0.05	   versus	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To	   our	   knowledge	   this	   is	   the	   first	   study	   comparing	   the	   anti-­‐hypertensive	   effects	   of	  
monotherapy	  with	  an	  ACE-­‐i	  or	  an	  ARB	  with	  dual	  therapy	  in	  patients	  with	  URAS.	  Our	  results	  
showed	  beneficial	  effects	  of	  dual	  therapy	  compared	  to	  either	  monotherapy	  in	  patients	  with	  
URAS,	  but	  only	  as	  regards	  to	  the	  casually	  measured	  blood	  pressure	  and	  not	  in	  the	  24	  hour-­‐
blood	   pressure	   measurements.	   So,	   the	   added	   effect	   of	   dual	   blockade,	   if	   anything,	   was	  
modest	   in	  this	  study.	  Previous	  studies	  with	  different	  group	  of	  patients	  [10-­‐14]	  suggest	  that	  
dual	   therapy	   with	   an	   ACE-­‐i	   and	   an	   ARB	   is	   more	   effective	   than	  monotherapy,	   though	   the	  
findings	  are	  not	  uniform.	  Recently,	  the	  ONTARGET	  trial	  was	  published	  [16],	  where	  maximum	  
dose	   of	   ramipril	   (10	   mg	   per	   day)	   was	   compared	   with	   80	   mg	   of	   telmisartan	   and	   the	  
combination	  of	  the	  two	  drugs	  in	  patients	  with	  vascular	  disease	  or	  high-­‐risk	  diabetes.	  In	  this	  
population,	   telmisartan	  was	  equivalent	   to	   ramipril.	   The	  combination	  of	   the	   two	  drugs	  was	  
associated	  with	  more	   adverse	   events	  without	   an	   increase	   in	   benefit.	   This	   landmark	   study	  
sheds	  light	  in	  how	  to	  interpret	  our	  data.	  It’s	  a	  well	  known	  fact	  that	  patients	  with	  ARAS	  often	  
have	   multiple	   comorbidities	   such	   as	   peripheral	   vascular	   disease	   [17]	   or	   coronary	   heart	  
disease	   [18].	   Therefore,	   optimal	   pharmacological	   treatment	   is	   essential.	   The	   STAR	   and	  
ASTRAL	   trial	   [3,	   4]	   have	   demonstrated	   that	   in	   patients	   with	   renal	   artery	   stenosis,	   stent	  
placement	  compared	  with	  medical	  treatment	  had	  no	  clear	  effect	  on	  progression	  of	  impaired	  
renal	   function.	   The	   study	   findings	   favor	   a	   conservative	   approach	   to	   patients	   with	   ARAS,	  
focused	   on	   cardiovascular	   risk	   factor	   management	   and	   avoiding	   stenting.	   Following	   the	  
ONTARGET	   trial,	   there	   is	   currently	   no	   evidence	   to	   treat	   patients	   with	   dual	   blockade	   and	  
given	  that	  our	  data	  didn’t	  show	  clear	   improvement	  of	  antihypertensive	  effects,	   there	   is	  no	  
support	   to	   treat	   renal	  artery	   stenosis	  patients	  with	  dual	  blockade.	  Furthermore,	   the	  blood	  
pressure	   in	   our	   patients	  was	   lower	  with	   their	   initial	   antihypertensive	  medication	   (10	  with	  
diuretic	   and	   7	   with	   triple	   therapy)	   suggesting	   that	   combination	   with	   another	   class	   of	  
antihypertensive	   is	  better	  that	  dual	  blockade	  alone.	  Some	  limitations	  to	  our	  study	  must	  be	  
considered.	  Mainly,	  for	  safety	  reasons,	  the	  washout	  period	  was	  very	  brief,	  and	  this	  may	  have	  
induced	  bias	   in	   the	  efficacy	  of	  particularly	   the	   first	  monotherapy	  period,	  due	   to	  carry-­‐over	  
effect.	   Whereas	   monotherapy	   was	   randomized	   in	   a	   parallel	   fashion,	   dual	   blockade	   was	  
always	  at	  the	  end	  of	  the	  study.	  Thus	  a	  time	  effect	  cannot	  be	  excluded.	  Secondly,	  the	  number	  
of	   eligible	   patients	   was	   very	   small	   –	   with	   consequently	   a	   relatively	   low	   power	   to	   detect	  
difference	  between	   the	  3	   regimens.	   Finally,	   doses	  were	  not	   titrated	   to	  a	  maximum	  effect.	  
 






These	  factors	  limit	  the	  possibility	  to	  draw	  definite	  conclusions	  about	  an	  added	  effect	  of	  the	  
combination	  therapy	  ACE-­‐i	  and	  ARB.	  However,	  the	  individual	  crossover	  design,	  starting	  with	  
monotherapy,	  nevertheless	  allows	   relevant	   inferences.	   In	  conclusion:	  dual	   therapy	  with	  an	  
ACE-­‐i	   and	   an	   ARB	   in	   patients	   with	   renovascular	   hypertension,	   due	   to	   URAS,	   was	   well	  
tolerated.	  The	  individual	  responses	  to	  monotherapy	  were	  concordant	  and	  the	  additive	  effect	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In	   patients	  with	   peripheral	   vascular	   disease	   (PVD)	  mortality	   is	   high.	   In	   this	   population	  
renal	   artery	   stenosis	   (RAS)	   is	   a	   frequent	   incidental	   finding.	   RAS	   carries	   a	   high	   risk	   for	  
mortality,	  but	  whether	  incidentally	  discovered	  RAS	  is	  a	  risk	  factor	  for	  mortality	  is	  unknown.	  
The	   prognostic	   impact	   of	   incidental	   RAS	   for	   mortality	   was	   studied	   in	   550	   consecutive	  
patients	  who	  underwent	   intra-­‐arterial	  digital	   subtraction	  angiography	   (DSA)	   for	  PVD	   in	  our	  
center	  between	  1997	  and	  2000.	  In	  491	  patients	  (336	  men,	  155	  women;	  mean	  follow-­‐up	  3.8	  ±	  
1.9	   years)	   the	   renal	   arteries	   were	   visualized	   and	   follow-­‐up	   data	   were	   available.	   RAS	  
(diameter	   reduction	  more	   than	  50	  %)	  was	  present	   in	  26%	  of	   the	  patients.	  Mortality	   in	   the	  
RAS	  group	  was	  59%	  versus	  28%	  in	  the	  non-­‐RAS	  group	  (odds	  ratio	  3.8;	  confidence	  interval	  2.5	  
to	   5.7,	   P	   <	   0.0001).	   Diabetes,	   previous	   myocardial	   infarction,	   history	   of	   PVD,	   stroke	   and	  
hypertension	  were	  more	   frequent	   in	   the	  RAS	  group;	  age	  was	  higher	  and	  GFR	  was	   lower	   in	  
the	  RAS	  group.	  Thus,	  RAS	  was	  associated	  with	  elevated	  mortality	  and	  increased	  prevalence	  
of	  cardiovascular	  risk	  factors.	  Cox-­‐regression	  analysis	  showed	  that	  RAS	  was	  an	  independent	  
predictor	   for	  mortality	   (P	  =	  0.005),	  along	  with	  age,	  diabetes,	   smoking,	  previous	  myocardial	  
infarction,	   history	   of	   PVD,	   and	   stroke.	   In	   patients	   who	   were	   evaluated	   for	   PVD	   by	   DSA	  
mortality	  was	  high.	  Incidental	  RAS	  was	  a	  frequent	  finding	  and	  an	  independent	  predictor	  for	  
mortality.	  Whether	  RAS	   is	  a	  marker	   for	  or,	  alternatively,	  a	  mediator	  of	   the	  poor	  prognosis	  
and	  whether	   prognosis	   can	   be	   improved	   by	   specific	   intervention	   should	   be	   the	   subject	   of	  
future	  prospective	  studies.	  








In	  patients	  with	  peripheral	  vascular	  disease	  mortality	  is	  high	  [1-­‐4],	  this	  is	  likely	  to	  be	  due	  
to	   the	   clustering	   of	   cardiovascular	   risk	   factors	   in	   these	   patients.	   When	   renal	   function	  
impairment	   is	   simultaneously	  present,	  mortality	   is	  even	  higher	   [5].	  Renal	  artery	   stenosis	   is	  
frequently	  encountered	  as	  an	  incidental	  finding	  in	  patients	  undergoing	  routine	  angiography	  
for	   PVD,	   with	   a	   prevalence	   between	   5	   and	   40%	   [6-­‐8].	   This	   corresponds	   to	   the	   high	  
prevalence	  of	  RAS	  (5	  to	  20%)	  in	  patients	  who	  undergo	  routine	  coronary	  angiography	  [9,10].	  
Atherosclerotic	   RAS	   is	   associated	   not	   only	   with	   hypertension,	   ischemic	   nephropathy	   and	  
cardiovascular	  disease	  [11,12],	  but	  also	  with	  a	  considerably	  increased	  mortality	  [13-­‐15].	  The	  
impact	   of	   RAS	   as	   a	   risk	   factor	   for	   mortality	   was	   established	   mainly	   in	   populations	   that	  
underwent	  a	  diagnostic	  work-­‐up	  for	  hypertension	  and/or	  renal	  failure.	  Data	  in	  patients	  who	  
underwent	   diagnostic	   cardiac	   catheterization	   simultaneously	   with	   an	   aortography	   [9,10]	  
showed	   that	   incidental	   RAS	   can	  be	   an	   independent	   risk	   factor	   for	  mortality.	  Whether	   this	  
holds	   also	   true	   for	   incidental	   RAS	   in	   PVD	   has	   not	   been	   established	   so	   far.	   We	   therefore	  
investigated	   the	   prognostic	   impact	   of	   incidental	   RAS	   for	  mortality	   in	   consecutive	   patients	  
who	  underwent	  intra-­‐arterial	  digital	  subtraction	  angiography	  (DSA)	  for	  PVD	  in	  a	  single	  center	  
between	  1997	  and	  2000.	  
	  
Materials	  and	  Methods	  
We	  reviewed	  a	  cohort	  of	  550	  consecutive	  patients	  who	  had	  clinically	  confirmed	  PVD	  by	  
noninvasive	  examinations	  (ankle-­‐brachial	   index	  or	  duplex	  Doppler	  of	  the	  lower	  extremities)	  
and	  underwent	  angiography	  with	  the	  intention	  of	  surgical	  or	  radiological	   intervention	  from	  
January	   1997	   to	   December	   2000	   in	   a	   single	   center,	   as	   judged	   by	   the	   vascular	   surgeons.	  
Patients	  in	  whom	  the	  angiogram	  did	  not	  allow	  proper	  assessment	  of	  the	  renal	  arteries	  were	  
excluded	  from	  the	  analysis.	  A	  single	  reviewer,	  blinded	  to	  patients’	  diagnoses	  and	  indications	  
for	   the	   procedure,	   evaluated	   the	   angiograms	   for	   RAS.	  A	   diameter	   reduction	  of	  more	   than	  
50%	  was	  considered	  diagnostic	   for	  presence	  of	  RAS;	   severe	   stenosis	  was	   considered	   to	  be	  
present	   when	   the	   stenosis	   exceeded	   75%	   [10].	   Clinical	   data	   were	   obtained	   from	   patient	  










Hypertension	   was	   defined	   according	   to	   the	   2003	   European	   Society	   of	   Hypertension-­‐
European	   Society	   of	   Cardiology	   guidelines	   for	   the	   management	   of	   arterial	   hypertension	  
[16,17],	  prescription	  of	  antihypertensive	  medications,	  or	  a	  clinical	  history	  of	  hypertension.	  A	  
patient	  was	  classified	  as	  having	  diabetes	   if	   there	  was	  a	  clinical	  history	  of	  diabetes	  or	   if	   the	  
patient	  was	  taking	  insulin	  or	  oral	  antidiabetic	  agents.	  We	  used	  the	  abbreviated	  Modification	  
of	   Diet	   in	   Renal	   Disease	   equation	   advocated	   in	   the	   Kidney	   Disease	   Outcomes	   Quality	  
Initiative	   guidelines	   [18]	   to	   estimate	   glomerular	   filtration	   rate	   (GFR).	   These	   data	   are	  
presented	  in	  the	  paper.	  In	  addition,	  we	  estimated	  GFR	  by	  the	  quadratic	  equation	  proposed	  
by	  Rule	  et	  al.	   [19],	  because	   this	  equation	   is	  assumed	  to	  provide	  a	  better	  estimate	  of	   renal	  
function	   in	  patients	   in	  whom	  renal	   function	   is	  normal	  or	  only	  mildly	   impaired.	  All	  analyses	  
were	   also	   performed	   using	   estimated	   GFR	   by	   the	   latter	   equation;	   this	   did	   not	   alter	   the	  
results	  (data	  not	  shown).	  
	  
Baseline	  characteristics	  
Eight	   clinical	   variables	   were	   recorded	   at	   baseline	   (i.e.,	   time	   of	   angiography):	   Serum	  
creatinine	  before	   angiography,	   history	   of	  myocardial	   infarction,	   history	  of	   stroke,	  diabetes	  
(present	   or	   absent),	   smoking	   history	   (ever/stopped	   or	   never),	   history	   of	   prior	   PVD	   (i.e.	  
previous	  treatment	  either	  conservative	  or	  not	  otherwise	  specified),	  history	  of	  hypertension	  
and	  current	  BP	  at	  time	  of	  angiography.	  
	  
Statistical	  analysis	  
Comparisons	   between	   groups	   (RAS	   versus	   non-­‐RAS)	   on	   baseline	   variables	   were	   done	  
using	   χ2	   test.	   Survival	   was	   assessed	   by	   Kaplan-­‐Meier	   curves,	   and	   to	   test	   for	   independent	  
predictors	  of	  mortality,	  we	  performed	  multivariate	  analysis	  using	  single-­‐step	  Cox	  regression	  
analysis.	   The	   renal	   function	   was	   classified	   according	   to	   the	   cutoffs	   recommended	   in	   the	  
Kidney	  Disease	  Outcomes	  Quality	   Initiative	   criteria	   [18]	   for	   defining	  moderate	   (GFR	   30-­‐60	  
ml/min/1.73m2)	   and	   severe	   (GFR	   <	   30	   ml/min/1.73m2)	   renal	   function	   impairment.	   	   All	  
statistical	   analyses	   were	   performed	   in	   SPSS	   12.0	   for	  Windows.	   Statistical	   significance	  was	  
defined	  as	  a	  P	  <	  0.05.	  
	  
	  








From	  January	  1997	  to	  December	  2000,	  550	  consecutive	  angiograms	  were	  performed	  in	  
patients	  with	  all	  confirmed	  PVD.	  The	  renal	  arteries	  could	  be	  assessed	  in	  their	  entirety	  for	  RAS	  
(diameter	  reduction	  >50%	  to	  75%	  and	  ≥75%)	  in	  499	  angiograms.	  The	  reasons	  for	  incomplete	  
visualization	  of	  the	  renal	  arteries	  were	  technical.	  Of	  the	  499	  assessable	  patients,	  eight	  could	  
not	  be	  included	  because	  of	  incomplete	  clinical	  data.	  Atherosclerotic	  RAS	  was	  present	  in	  129	  
(26%)	  of	  the	  491	  patients;	  of	  these	  patients,	  35	  (27%)	  had	  a	  luminal	  RAS	  of	  more	  than	  75%,	  




Baseline	   characteristics	   of	   the	   population	   are	   presented	   in	   Table	   1	   and	   were	   divided	  
according	  to	  presence	  or	  absence	  of	  RAS.	  Patients	  with	  RAS	  were	  significantly	  older	  and	  their	  
mortality	  was	  significantly	  higher	  than	  in	  patients	  without	  RAS	  (59%	  and	  28%,	  respectively;	  
P<0.0001).	   In	   patients	   with	   RAS,	   the	   prevalence	   of	   several	   cardiovascular	   risk	   factors	  
(hypertension,	   diabetes,	   previous	   history	   of	   PVD,	   myocardial	   infarction	   and	   stroke)	   was	  
higher	  than	  in	  patients	  without	  RAS,	  but	  the	  proportion	  of	  smokers,	  remarkably,	  was	  lower	  
in	   the	   group	   with	   RAS.	   As	   shown	   by	   the	   Kaplan-­‐Meier	   survival	   curves	   in	   Figure	   1,	   the	  
estimated	  5-­‐year	  survival	  probability	  was	  37%	  for	  patients	  with	  RAS	  as	  compared	  with	  72%	  
for	   patients	   without	   RAS	   (odds	   ratio	   of	   3.76).	   Patients	   with	   moderate	   and	   severe	   renal	  
function	  impairment	  were	  overrepresented	  among	  the	  patients	  with	  RAS	  as	  compared	  with	  
the	  group	  without	  RAS	  (Table	  2).	  Among	  patients	  with	  RAS	  ≥75%	  the	  majority	  had	  moderate	  
or	  severe	  renal	  function	  impairment,	  whereas	  this	  amounted	  to	  approximately	  one-­‐third	  of	  







versus	   54.8	   ±	   26.4	  ml/min	   for	   RAS	   ≥	   75%	   (P	   =	   0.016).	   Therefore,	   RAS	   and	   its	   severity	   are	  
associated	  with	  the	  severity	  of	  renal	  function	  impairment.	  The	  association	  of	  renal	  function	  





The	  crude	  mortality	  rates	  by	  absence	  or	  presence	  and	  severity	  of	  RAS	  is	  given	  in	  Table	  3,	  
showing	   significant	   effects	   of	   presence	   and	   severity	   of	   RAS	   on	   mortality,	   both	   for	   the	  
population	  as	  a	  whole	  and	  after	  stratification	  of	  GFR	  in	  each	  of	  the	  various	  strata	  of	  GFR,	  i.e.,	  
normal	   tot	   mildly	   impaired	   renal	   function	   (GFR	   >60	   ml/min),	   moderately	   impaired	   renal	  
function	   (GFR	   30	   to	   60	   ml/min)	   and	   severely	   impaired	   renal	   function	   (GFR	   <30	   ml/min).	  
Mortality	   was	   particularly	   high	   in	   patients	   with	   moderate	   and	   severe	   renal	   function	  
impairment.	   Time-­‐dependent	   survival	   by	   presence	   or	   absence	   of	   RAS,	   and	   by	   stratum	   of	  
Figure	   1.	   Kaplan-­‐Meier	   survival	   plots	   for	  
491	   patients	   with	   peripheral	   vascular	  
disease,	   comparing	   outcome	   for	   those	  
without	   renal	   artery	   stenosis	   (NRAS)	   and	  
those	  with	  renal	  artery	  stenosis	  (RAS).	  
	  







renal	  function	  is	  shown	  as	  Kaplan-­‐Meier	  curves	   in	  Figure	  2.	   It	  shows	  that	  RAS	  and	  GFR	  <60	  
ml/min	  both	  were	  associated	  with	  worse	  survival,	  with	  the	  poorest	  survival	  in	  patients	  with	  
both	  RAS	  and	  GFR	  <60	  ml/min	   (overall	   log	  rank	  test	  χ2	  P	  <0.0001;	  group	  1	  versus	  group	  2:	  
P=0.0025;	   relative	   risk	   [RR]	   1.89,	   95%	   confidence	   interval	   [CI]	   1.31-­‐3.49);	   group	   3	   versus	  
group	  1	  P<0.0001,	  RR:	  2.44,	  95%	  CI	  1.92	  to	  5.41;	  group	  4	  versus	  group	  1:	  P<0.0001,	  RR	  4.61,	  




The	   independent	   contribution	  of	   the	  various	   risk	   factors	   for	  mortality	  was	  assessed	  by	  
Cox-­‐regression	   analysis,	   as	   shown	   in	   Table	   4.	   It	   shows	   first	   the	   crude	  model,	   in	  which	   the	  
widely	   known	   cardiovascular	   risk	   factors	   age,	   diabetes,	   history	   of	   previous	   PVD,	   smoking,	  
Figure	   2.	   Kaplan-­‐Meier	  
survival	   plots	   for	   patients	  
with	   PVD	   and	   GFR	   >	   60	  
ml/min	  per	  1.73	  m2	  and	  GFR	  
<60	   ml/min	   per	   1.73	   m2,	  
comparing	   outcome	   for	  








previous	   myocardial	   infarction	   and	   previous	   stroke,	   were	   independent	   predictors	   for	  
mortality.	   The	   contribution	   of	   stratum	  of	   renal	   function	   reached	   significance	   only	   for	  GFR	  
<30	  ml/min	  (P	  =	  0.047).	  When	  the	  model	  was	  adjusted	  for	  presence	  of	  RAS,	  the	  contribution	  
of	   class	   of	   renal	   function	  was	   attenuated,	  whereas	   RAS	  was	   an	   independent	   predictor	   for	  





Our	   data	   confirm	   that	   incidental	   RAS	   is	   a	   frequent	   finding	   in	   patients	   evaluated	   for	  
peripheral	  vascular	  disease	  by	  DSA.	  The	  main	  finding	  of	  our	  paper	  is	  that	  we	  demonstrated,	  
for	   the	   first	   time,	   that	   RAS	   is	   an	   independent	   predictor	   of	   mortality	   in	   this	   population.	  
Moreover,	   we	   found	   that	   incidental	   RAS	   was	   closely	   associated	   with	   the	   level	   of	   renal	  
function.	  Remarkably,	  the	  prognostic	  impact	  of	  incidental	  RAS	  was	  true	  both	  in	  patients	  with	  
normal	   or	  mild	   renal	   function	   impairment,	   and	   in	   patients	  with	  moderate	   to	   severe	   renal	  
insufficiency.	  
The	   prevalence	   of	   incidental	   atherosclerotic	   RAS	   in	   our	   population	  was	   26%,	  which	   is	  
well	  within	  the	  range	  observed	  in	  other	  studies	  on	  PVD,	  in	  which	  prevalences	  ranged	  from	  5	  







to	  40%	  [6-­‐8].	  Prevalence	  obviously	  can	  be	  confounded	  by	  the	  definition	  used;	  our	  definition	  
of	  RAS	   (a	  50%	  reduction	   in	   renal	  artery	   lumen)	   is	   in	   line	  with	  similar	   studies	  on	  survival	   in	  
coronary	  artery	  disease	  [9,10],	  and	  our	  cutoff	  for	  severe	  stenosis	  (≥75%	  luminal	  narrowing)	  
is	  in	  accordance	  with	  the	  study	  described	  by	  Conlon	  et	  al.	  [10].	  
In	  patients	  with	  PVD,	  mortality	  is	  high.	  McKenna	  et	  al.	  [1]	  found	  a	  5-­‐year	  survival	  of	  44%	  
in	   patients	  with	   PVD	   (as	   demonstrated	   by	   an	   ankle-­‐brachial	   index	   of	   <0.4)	   versus	   an	   85%	  
survival	   in	   patients	  without	   vascular	   disease.	   Criqui	  et	   al.	   [2]	   reported	   a	   5-­‐year	   survival	   of	  
70%	   in	   patients	   with	   symptomatic	   PVD	   versus	   90%	   in	   normal	   individuals.	   When	   renal	  
insufficiency	  was	  present	   concomitantly,	  mortality	  was	   even	  higher,	  with	   a	   1-­‐year	   survival	  
rate	  of	  56%	  for	  patients	  with	  a	  GFR	  <30	  ml/min	  per	  1.73	  m2	  compared	  with	  83%	  for	  patients	  
with	  a	  GFR	  >60	  ml/min	  per	  1.73	  m2	  [5].	  The	  overall	  mortality	   in	  our	  patients	  is	   in	  line	  with	  
these	   studies,	   but	   our	   data	   also	   show	   that	   the	   subgroup	  with	   RAS	   has	   a	   prognosis	   that	   is	  
considerably	  worse.	  Also,	   in	  patients	  with	  symptomatic	  RAS,	  mortality	   is	   increased,	  but	  the	  
reported	  mortality	  rates	  are	  lower	  than	  in	  our	  patients	  with	  RAS.	  Isles	  et	  al.	  [14]	  reported	  a	  
5-­‐year	   survival	   probability	   of	   83%	   for	   patients	   with	   renovascular	   hypertension,	   and	  
Wollenweber	   et	   al.	   [13]	   found	   a	   5-­‐year	   survival	   of	   67%	   for	   patients	   with	   atherosclerotic	  
renovascular	  disease	  versus	  90%	  for	  the	  general	  population.	  A	  more	  recent	  study	  by	  Wright	  
et	  al.	   [15]	   showed	  a	  mortality	   rate	  of	  35.7%	   for	  patients	  with	  atherosclerotic	   renovascular	  
disease	   using	   a	   mean	   follow-­‐up	   of	   27.7	   months.	   Whereas	   a	   direct	   comparison	   is	   not	  
warranted,	  our	  data	  nevertheless	  suggest	  that	  incidental	  RAS	  in	  patients	  with	  PVD	  carries	  a	  
particularly	  poor	  prognosis,	  especially	   in	  patients	  with	  moderate	  to	  severe	  renal	   failure	   (of	  
whatever	  cause).	  
What	  would	  be	  the	  implications	  of	  our	  findings?	  First,	  our	  study	  is	  the	  first	  to	  allow	  for	  
mutual	  association	  between	  RAS,	   renal	   function	   impairment	  and	  mortality	   in	  patients	  with	  
PVD.	   These	   data	  may	   provide	   a	   potential	   pathogenic	   link	   between	   the	   association	   of	   PVD	  
and	   renal	   insufficiency	   [20]	   and	   the	   association	   between	   renal	   function	   impairment	   and	  
increased	  mortality	  in	  patients	  with	  PVD	  as	  described	  by	  O’Hare	  et	  al.	  [5],	  respectively.	  Our	  
data	  suggest	  that	  a	  considerable	  proportion	  of	  the	  presence	  of	  renal	  function	  impairment	  in	  
PVD	  can	  be	  ascribed	  to	  the	  presence	  of	  RAS	  but	  do	  not	  allow	  a	  conclusive	  dissection	  as	  to	  
which	  of	  the	  two	  is	  the	  main	  causal	  factor	  for	  mortality.	  It	  is	  remarkable	  in	  this	  respect	  that	  
adjustment	   for	  RAS	  attenuated	  the	   impact	  of	  renal	   function	   in	  the	  multivariate	  model,	  but	  







disentangle	  their	  respective	  impact,	  so	  whether	  RAS	  is	  an	  independent	  causal	  factor	  remains	  
hypothetical.	   In	  principle,	  RAS	   in	   itself	   can	  exerts	  deleterious	  pathophysiological	  effects	  by	  
excess	   production	   of	   angiotensin	   II	   [21],	   which	   is	   a	   potent	   vasoconstrictor	   that	   has	   been	  
implicated	  in	  the	  activation	  of	  cell	  proliferation	  systems	  [22].	  High	  levels	  of	  angiotensin	  II	  are	  
associated	   with	   left	   ventricular	   hypertrophy,	   endothelial	   dysfunction	   and	   target	   organ	  
damage	   [23].	   This	   pathway	   could	   explain,	   at	   least	   partially,	   the	   increased	   mortality	   in	  
symptomatic	   atherosclerotic	   RAS.	   If	   this	  would	   be	   the	   case,	   it	  would	   be	   logical	   to	   assume	  
that	  pharmacological	  blockade	  of	  the	  renin-­‐angiotensin	  aldosterone	  system	  might	  have	  the	  
potential	   to	   ameliorate	   the	   poor	   prognosis,	   but	   obviously	   this	   assumption	   would	   need	  
empirical	  substantiation.	  
Second,	   our	   data	   suggest	   that	   incidentally	   found	  RAS	   can	   serve	   as	   a	  marker	   of	   a	   poor	  
prognosis.	  When	  RAS	  is	  present,	  it	  is	  a	  strong	  marker	  of	  extended	  cardiovascular	  disease	  as	  
suggested	   by	   the	  well-­‐established	   clinical	   predictors	   of	   incidental	   RAS.	   Therefore,	   it	   could	  
well	  be	  a	  marker	  of	  more	  extended	  coronary	  or	  cerebrovascular	  disease	  and	  thus	  related	  to	  
increased	  mortality.	   In	   this	   perspective,	   it	   has	   been	   shown	   that	   in	   patients	   who	   undergo	  
diagnostic	   cardiac	   catheterization	   simultaneously	  with	   an	   aortography,	   incidental	   RAS	  was	  
an	  independent	  risk	  factor	  for	  mortality	  [9,10].	  Moreover,	  the	  severity	  of	  RAS	  was	  related	  to	  
mortality.	   In	   our	   study,	   however,	   no	   appropriate	   characterization	   of	   coronary	   or	  
cerebrovascular	  disease	  was	  available,	  because	  the	  patients	  all	  were	  referred	  to	  the	  hospital	  
by	  the	  general	  practitioner	  because	  of	  suspicion	  of	  PVD	  and	  were	  evaluated	  and	  treated	  by	  
the	  vascular	   surgeon	  only.	   Therefore,	   a	  possible	   relationship	  between	  RAS	  and	   its	   severity	  
and	  coronary	  artery	  disease	  cannot	  be	  made	  for	  our	  population.	  
As	   anticipated,	   several	   well-­‐established	   clinical	   predictors	   of	   incidental	   RAS,	   namely	  
older	  age	   [24-­‐26],	  hypertension	   [24,25,27,28],	   impaired	   renal	   function	   [24,28],	  a	  history	  of	  
coronary	   artery	   disease	   [9,10,24,26],	   and	   diabetes	   [25,27,28]	  were	  more	   prevalent	   in	   our	  
group	  with	  RAS,	  with	  the	  exception,	  however,	  of	  a	  history	  of	  smoking	  [25,27].	  This	  seeming	  
discrepancy	  may	  be	  due	  to	  bias	  by	  indication,	  because	  the	  patients	  with	  RAS	  were	  older	  and	  
had	   more	   symptomatic	   comorbidity,	   and	   therefore	   were	   more	   likely	   to	   have	   received	  
previous	  advice	   to	  stop	  smoking.	  Whereas	   the	  difference	   in	  prevalence	  of	   risk	   factors	  may	  
have	   contributed	   to	   the	   overall	   difference	   in	   mortality,	   the	   Cox	   regression	   analysis	  
demonstrated	  the	  independent	  contribution	  of	  RAS.	  	  







The	  clinical	  implications	  of	  incidentally	  discovered	  RAS	  so	  far	  are	  uncertain.	  Studies	  on	  
its	   natural	   history	   [6,15,29,30]	   reported	   that	   progression	   to	   end	   stage	   renal	   failure	   is	   rare	  
[6,7].	  From	  the	  perspective	  of	  preservation	  of	  renal	  function,	  therefore,	  revascularization	  is	  
not	  recommended	  for	  patients	  with	  incidentally	  discovered	  RAS	  [6,7].	  It	  may	  be	  worthwhile	  
to	   refer	   these	   patients	   to	   the	   internist	   or	   cardiologist	   for	   a	   thorough	   screening	   for	  
cardiovascular	  disease	  and	  for	  aggressive	  cardiovascular	  preventive	  therapy.	  It	  is	  known	  that	  
aggressive	   treatment	   of	   hypertension	   and	   strict	   regulation	   of	   diabetes	   improves	  
cardiovascular	  morbidity	   and	  mortality	   [31-­‐33],	   and	   that	   an	   intensive	   lipid-­‐lowering	   statin	  
regimen	  can	  improve	  prognosis	  in	  high-­‐risk	  populations	  [34].	  	  
Some	  limitations	  of	  our	  study	  should	  be	  considered.	  Because	  this	  was	  a	  retrospective	  
post	  hoc	   analysis,	  we	  were	  not	  able	   to	  evaluate	  all	  of	   the	   renal	  arteries	   in	   the	  patients.	   In	  
addition,	   all	   but	   eight	   patients	  were	   included	   in	   the	   follow-­‐up.	  Unfortunately,	   the	   specific	  
number	  of	  deaths	  due	  to	  cardiovascular	  problems	  is	  not	  known	  because	  cause	  of	  death	  was	  
not	   specified	   in	   our	   patient	   data	   and	  our	   hospital	   information	   system	  was	  not	   linked	   to	   a	  
national	   registry	   for	   death	   registration.	   All	   the	   angiograms	   were	   performed	   in	   the	   same	  
center;	   as	   a	   result,	   it	   may	   influence	   the	   generalizability	   of	   our	   findings.	   However,	   all	  
angiographies	  were	  analyzed	  by	  the	  same	  radiologist,	  who	  was	  blinded	  to	  patient	  diagnosis	  
and	   indications,	   so	   there	  were	   no	   inter-­‐observer	   variances.	   In	   the	   patient	   records,	   it	   was	  
remarkable	  that	  hardly	  any	  of	  these	  patients	  were	  under	  medical	  supervision	  by	  an	  internist	  
or	  a	  nephrologist.	  This	  may	  be	  because	  all	  our	  patients	  described	  were	  referred	  by	  general	  
practitioners	  to	  the	  vascular	  surgeon.	  Our	  patients,	  therefore,	  may	  well	  be	  representative	  for	  
those	   referred	   for	   angiography	   for	   evaluation	   for	   PVD.	   However,	   it	   may	   not	   be	  
representative	  for	  the	  whole	  PVD	  population,	  because	   it	   is	  known	  that	  many	  patients	  with	  
PVD	  go	  unrecognized	  in	  general	  practice	  [35].	  	  
	  
Conclusion	  
Incidental	  RAS	   is	  a	  frequent	  finding	   in	  patients	  who	  are	  evaluated	  for	  PVD	  by	  DSA,	  and	  
this	  finding	  predicts	  mortality	   independent	  of	  other	  risk	  factors.	  Therefore,	  risk	  assessment	  
in	   patients	  who	   undergo	   angiography	   for	   PVD	   could	   be	   improved	   by	   consideration	   of	   the	  
renal	   arteries.	   Future	   prospective	   studies	   should	   examine	   whether	   RAS	   is	   a	   marker	   or	  
mediator	  of	  poor	  prognosis	  and	  whether	  prognosis	  can	  be	  improved	  by	  specific	  intervention	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Objective:	   In	   peripheral	   arterial	   disease	   (PAD)	   mortality	   is	   high.	   Incidental	   renal	   artery	  
stenosis	  (RAS)	  is	  a	  predictor	  of	  mortality	  in	  PAD	  patients	  undergoing	  angiography.	  This	  might	  
be	  relevant	  for	  risk-­‐benefit	  assessment	  when	  vascular	  surgery	  is	  considered,	  both	  in	  terms	  of	  
perioperative	  risk,	  and	  in	  terms	  of	  life	  expectancy.	  
Methods:	  We	  studied	  the	  prognostic	  impact	  of	  incidental	  RAS	  in	  488	  subjects	  (334	  men,	  154	  
women;	  mean	   follow-­‐up	   6.0	   ±3.4	   years)	   who	   underwent	   angiography	   for	   PAD	   in	   a	   single	  
center	   between	   1997	   and	   2000.	   Renal	   arteries	   were	   visualized	   and	   follow-­‐up	   data	  
concerning	  vascular	  procedures	  analyzed.	  	  
Results:	   RAS	   (diameter	   reduction	   >50	   %)	   was	   present	   in	   26%.	   Forty-­‐six	   percent	   of	   study	  
patients	   underwent	   a	   vascular	   procedure	   (85%	   vascular	   surgery,	   remainder	   underwent	  
amputation).	   Patients	   that	   underwent	   vascular	   surgery	   had	   a	   better	   renal	   function	   at	  
baseline,	   less	   history	   of	   stroke,	   and	   a	   larger	   proportion	   of	   smokers.	  Overall	  mortality	  was	  
similar	   for	   patients	   that	   underwent	   surgery	   (54.5%)	   and	   those	   without	   surgery	   (49.6%).	  
There	  was	  no	  difference	  in	  90-­‐day	  postoperative	  mortality	  for	  patients	  without	  or	  with	  RAS	  
(7.2%	   vs	   10.3%;	   NS).	   For	   subjects	   that	   underwent	   bypass	   surgery,	   long-­‐mortality	   was	  
substantially	   and	   significantly	   higher	   among	   those	  with	   RAS	   (65.1%)	   vs	   those	  without	   RAS	  
(43.5%).	   On	   Cox	   regression	   analysis,	   age	   was	   the	   only	   independent	   predictor	   of	   90	   days	  
postoperative	  mortality.	  The	  well-­‐known	  cardiovascular	  risk	  factors	  of	  age,	  diabetes	  mellitus,	  
history	   of	   prior	   peripheral	   vascular	   disease,	   smoking,	   prior	   myocardial	   infarction,	   prior	  
stroke,	  and	  amputation,	  as	  well	  as	  presence	  of	  RAS,	  were	  independent	  predictors	  for	  overall	  
mortality.	  	  
Conclusion:	   In	   PAD	   incidental	   RAS	   predicts	   long-­‐term	  mortality	   independent	   of	   other	   risk	  
factors.	  The	  elevated	  mortality	  is	  not	  due	  to	  a	  higher	  postoperative	  risk.	  Subjects	  presenting	  
with	  PAD	  and	  RAS	  can	   therefore	  undergo	  vascular	  procedures	  with	   the	   same	  risk	  as	  other	  
patients.	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In	   patients	   with	   peripheral	   arterial	   disease,	   mortality	   is	   high	   [1-­‐3]	   and	   is	   most	   likely	  
related	  to	  the	  clustering	  of	  cardiovascular	  risk	  factors	  in	  these	  patients.	  When	  renal	  function	  
impairment	   is	   simultaneously	  present,	  mortality	   is	  even	  higher	   [4].	  Renal	  artery	   stenosis	   is	  
frequently	  encountered	  as	  an	  incidental	  finding	  in	  patients	  undergoing	  routine	  angiography	  
for	  PAD,	  with	  prevalence	  between	  5	  and	  40%	  [5-­‐7].	  We	  have	  previously	  demonstrated	  that	  
incidental	   RAS	   is	   an	   independent	   predictor	   of	   a	   substantially	   elevated	   mortality	   in	   PAD	  
patients	  [6].	  The	  hypothesis	  is	  that	  patients	  with	  incidental	  RAS	  have	  higher	  mortality	  due	  to	  
higher	  postoperative	  risk.	  This	  might	  be	  relevant	  for	  risk-­‐benefit	  assessment	  when	  vascular	  
surgery	   is	   considered,	  both	   in	   terms	  of	  perioperative	   risk,	   and	   in	   terms	  of	   life	  expectancy.	  
Therefore,	  we	   investigated	  the	  prognostic	   impact	  of	   incidental	  RAS	  for	   long-­‐term	  mortality	  
as	  well	  as	  perioperative	  mortality	  in	  a	  cohort	  of	  consecutive	  subjects	  who	  underwent	  intra-­‐
arterial	  digital	  subtraction	  angiography	  for	  PAD	   in	  a	  single	  center	  between	  1997	  and	  2000,	  




Design	  of	  the	  study.	  For	  the	  cohort	  of	  550	  consecutive	  patients	  described	  previously	  [6],	  
with	   clinically	   confirmed	   PAD	   by	   noninvasive	   examinations	   (i.e.,	   ankle-­‐brachial	   index	   or	  
duplex	   ultrasound	   of	   the	   lower	   extremities),	   patient	   records	  were	   reviewed,	   and	   detailed	  
additional	   data	   regarding	   vascular	   procedures	   were	   extracted.	   Briefly,	   these	   were	  
subsequent	  patients,	   diagnosed	  between	  1997	  and	  2000.	   For	   the	   current	   study,	   follow-­‐up	  
for	   mortality	   (in	   the	   previous	   report	   until	   2004)	   was	   extended	   until	   January	   1,	   2008,	  
amounting	  to	  a	  mean	  follow-­‐up	  time	  of	  6	  years.	  All	  patients	  underwent	  angiography	  with	  the	  
intention	  of	  surgical	  or	  radiological	   intervention	  from	  January	  1997	  to	  December	  2000	   in	  a	  
single	  center,	  as	  judged	  by	  the	  vascular	  surgeons.	  Patients	  in	  whom	  the	  angiography	  did	  not	  
allow	   proper	   assessment	   of	   the	   renal	   arteries	   were	   excluded	   from	   the	   analysis.	   A	   single	  
reviewer	  (H.H.),	  blinded	  to	  patients’	  diagnoses	  and	  indications	  for	  the	  procedure,	  evaluated	  
the	  angiograms	  for	  the	  presence	  of	  renal	  artery	  stenosis.	  A	  diameter	  reduction	  of	  >50%	  was	  
considered	  diagnostic	  for	  the	  presence	  of	  RAS;	  severe	  stenosis	  was	  considered	  to	  be	  present	  
when	   the	   stenosis	   exceeded	   75%	   [8].	   Clinical	   data,	   including	   surgical	   or	   radiological	  







were	   obtained	   from	   the	   hospital	   information	   system.	   The	   Institutional	   Review	   Board	  
approved	  this	  study.	  	  
Definitions.	   Hypertension	   was	   defined	   according	   to	   the	   2007	   European	   Society	   of	  
Hypertension-­‐European	   Society	   of	   Cardiology	   guidelines	   for	   the	   management	   of	   arterial	  
hypertension	   [9],	   prescription	   of	   antihypertensive	   medications,	   or	   a	   clinical	   history	   of	  
hypertension.	   A	   patient	  was	   classified	   as	   having	   diabetes	   if	   there	  was	   a	   clinical	   history	   of	  
diabetes	   or	   if	   the	   patient	   was	   taking	   insulin	   or	   oral	   anti-­‐diabetic	   agents.	   We	   used	   the	  
abbreviated	  Modification	  of	  Diet	  in	  Renal	  Disease	  (MDRD)	  equation	  advocated	  in	  the	  Kidney	  
Disease	  Outcomes	  Quality	  Initiative	  (KDOQI)	  guidelines	  [10]	  to	  estimate	  glomerular	  filtration	  
rate	  (GFR).	  
Baseline	  characteristics.	   Eight	   clinical	   variables	  were	   recorded	  at	  baseline	   (i.e.,	   time	  of	  
angiography):	  the	  serum	  creatinine	  before	  angiography;	  a	  history	  of	  myocardial	  infarction;	  a	  
history	   of	   stroke;	   diabetes	  mellitus	   (present	   or	   absent);	   smoking	   history	   (ever/stopped	   or	  
never);	   history	   of	   prior	   PAD	   (i.e.,	   previous	   treatment	   either	   conservative	   or	   not	   otherwise	  
specified);	  history	  of	  hypertension;	  and	  current	  blood	  pressure	  at	  time	  of	  angiography.	  
Vascular	  procedures.	   Vascular	  procedures	  were	  defined	  as	  either	   a	   surgical	   procedure	  
(i.e.,	   primary	   vascular	   bypass	   operation	   or	   amputation)	   or	   endovascular	   treatment	   (i.e.,	  
revascularization	  with	  primary	  percutaneous	  transluminal	  angioplasty).	  
Statistical	   analysis.	   Comparisons	   between	   groups	   (renal	   artery	   stenosis	   vs	   nonrenal	  
artery	   stenosis)	   on	   baseline	   variables	   were	   performed	   using	   Pearson	   χ2test.	   Survival	   was	  
assessed	   by	   Kaplan-­‐Meier	   curves,	   and	   to	   test	   for	   independent	   predictors	   of	   mortality,	  
multivariate	   analysis	   was	   performed	   using	   single-­‐step	   Cox	   regression	   analysis.	   The	   renal	  
function	  was	  classified	  according	  to	  the	  cut-­‐offs	  recommended	  in	  the	  KDOQI	  criteria	  [10]	  for	  
defining	  moderate	  (GFR	  30-­‐60	  ml/min/1.73m2)	  and	  severe	  (GFR	  <	  30	  ml/min/1.73m2)	  renal	  
function	  impairment.	  All	  statistical	  analyses	  were	  performed	  in	  SPSS	  14.0	  for	  Windows	  SPSS,	  
Chicago,	  Ill).	  Statistical	  significance	  was	  defined	  as	  a	  P	  value	  <.05.	  
	  
RESULTS	  
From	  January	  1997	  to	  December	  2000,	  550	  consecutive	  angiograms	  were	  performed	  in	  
patients,	   all	  with	   confirmed	  PAD.	  The	   renal	  arteries	   could	  be	  assessed	   in	   their	  entirety	   for	  
renal	   artery	   stenosis	   (diameter	   reduction	   >50%-­‐75%	   and	   ≥75%)	   in	   499	   angiograms.	   The	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reasons	   for	   incomplete	   visualization	   of	   the	   renal	   arteries	   were	   technical.	   Of	   the	   499	  
evaluable	   patients,	   11	   patients	   could	   not	   be	   included	   because	   of	   incomplete	   clinical	   data.	  
Atherosclerotic	  renal	  artery	  stenosis	  was	  present	  in	  128	  (26%)	  of	  the	  488	  patients;	  of	  these	  
patients,	  35	  (27%)	  had	  a	  luminal	  renal	  artery	  stenosis	  of	  more	  than	  75%,	  and	  73	  (57%)	  had	  a	  
bilateral	  renal	  artery	  stenosis.	  
Baseline	   characteristics	   of	   the	   population	   are	   presented	   in	   Table	   I,	   by	   a	   break-­‐up	  
according	  to	  whether	  or	  not	  surgery	  was	  performed.	  Of	  the	  224	  patients	  that	  underwent	  a	  
vascular	   procedure,	   190	   (85%)	   had	   vascular	   surgery;	   the	   remainder	   underwent	   an	  
amputation.	   Patients	   that	   underwent	   vascular	   surgery	   had	   a	   better	   renal	   function	   at	  
baseline,	   less	   history	   of	   stroke,	   and	   a	   larger	   proportion	   of	   smokers,	   suggesting	   impact	   of	  
patient	   selection	   for	   surgery.	   Long-­‐term	  mortality	  was	   similar	   for	   patients	   that	   underwent	  




Table	   II	   shows	   the	   baseline	   characteristics	   of	   patients	   who	   underwent	   percutaneous	  
transluminal	  angioplasty	  (PTA)	  compared	  with	  vascular	  surgery.	  There	  was	  no	  difference	   in	  
short-­‐term	   mortality;	   only	   long-­‐term	   mortality	   was	   slightly	   elevated	   in	   patients	   who	  
underwent	  vascular	  surgery.	  There	  was	  no	  difference	  in	  the	  renal	  function	  or	  the	  other	  risk	  
factors	  between	   the	  groups.	  Patients	  with	  RAS	  were	  older	  and	  had	  a	  higher	  prevalence	  of	  
cardiovascular	  risk	  factors	  (Table	  III).	  In	  Table	  IV,	  mortality	  data	  are	  presented	  by	  a	  break-­‐up	  
by	  presence	  or	  absence	  of	  RAS,	  for	  patients	  that	  underwent	  surgery	  and	  those	  who	  had	  not.	  
Among	   the	   patients	   that	   underwent	   surgery,	  mortality	  was	   extremely	   high	   for	   those	  with	  







underwent	  bypass	  surgery,	  mortality	  was	  substantially	  and	  significantly	  higher	  among	  those	  
with	  RAS	  (65.1%)	  versus	  those	  without	  RAS	  (43.5%).	  There	  were	  no	  differences,	  however,	  in	  
90-­‐day	  and	  1-­‐year	  postoperative	  mortality	  for	  patients	  with	  RAS	  as	  compared	  with	  no	  RAS,	  
and	   there	   was	   no	   difference	   in	   mortality	   between	   patients	   with	   unilateral	   RAS	   versus	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As	  shown	  by	   the	  Kaplan-­‐Meier	   survival	   curves	   in	   the	  Fig,	   the	  estimated	  5-­‐	  and	  10-­‐year	  
survival	   probability	   for	   patients	   who	   did	   not	   undergo	   a	   vascular	   procedure	   was	   72%	   and	  
55%,	  respectively,	  for	  patients	  without	  RAS	  as	  compared	  with	  36%	  and	  24%,	  respectively,	  for	  
patients	   with	   RAS.	   The	   estimated	   5-­‐	   and	   10-­‐year	   survival	   probability	   for	   patients	   with	   a	  
vascular	   procedure	   in	   the	   group	  without	   RAS	  was	   66%	   and	   50%,	   respectively,	   versus	   42%	  




The	   independent	   contribution	   of	   the	   various	   risk	   factors	   for	   90-­‐day	   postoperative	  
mortality	   and	   long-­‐term	  mortality	   were	   assessed	   by	   Cox	   regression	   analysis,	   as	   shown	   in	  
Table	   VI	   and	   VII,	   respectively.	   For	   the	   90-­‐day	   postoperative	   mortality,	   age	   was	   the	   only	  







history	   of	   prior	   peripheral	   vascular	   disease,	   smoking,	   prior	   myocardial	   infarction,	   prior	  







In	   our	   previous	   study,	   we	   demonstrated	   that	   the	   mortality	   in	   patients	   with	   PAD	   is	  
extremely	   high,	   especially	   in	   patients	   with	   concomitant	   incidental	   RAS	   and	   PAD.	   As	  
previously	  demonstrated,	  incidental	  RAS	  is	  an	  independent	  predictor	  of	  long-­‐term	  mortality	  
in	   patients	   with	   PAD	   [6].	   In	   this	   study,	   we	   have	   examined	   the	   contribution	   of	   the	  
perioperative	  mortality	  on	  the	  total	  (5-­‐	  and	  10-­‐year)	  mortality.	  In	  contrast	  to	  our	  hypothesis	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or	   previous	   ideas	   [11],	   this	   mortality	   was	   not	   influenced	   by	   the	   operative	   procedures,	  
irrespective	  of	  the	  patient	  had	  a	  RAS	  or	  not.	  The	  90-­‐day	  and	  1-­‐year	  postoperative	  mortality	  
was	  not	  significantly	  different	  in	  patients	  with	  and	  without	  RAS.	  In	  terms	  of	  life	  expectancy,	  
patients	  with	   incidental	  RAS	  have	  higher	  mortality	   in	   comparison	   to	  patients	  without	  RAS;	  
however,	  this	  is	  not	  due	  to	  postoperative	  short	  (90	  days)	  or	  midterm	  (1	  year)	  mortality.	  
The	  association	  between	  renal	   function	  and	   increased	  mortality	   in	  patients	  with	  PAD	  
undergoing	  lower	  extremity	  bypass	  surgery	  has	  previously	  been	  described	  in	  this	  journal	  by	  
O’Hare	  et	  al.	  [12]	  and	  Owens	  et	  al.	  [4].	  The	  first	  study	  found	  that	  patients	  receiving	  dialysis	  
have	  a	  high	  incidence	  of	  amputation	  within	  1	  year	  of	  lower	  extremity	  revascularization	  that	  
is	   not	   explained	   by	   a	   higher	   prevalence	   of	   demographic	   characteristics	   and	   comorbid	  
conditions.	   The	   second	   study	   demonstrated	   that	   in	   their	   cohort	   of	   456	   subjects,	   patients	  
with	   more	   severe	   renal	   insufficiency	   had	   significantly	   higher	   mortality	   and	   lower	  
amputation-­‐free	   survival	   following	   lower	   extremity	   revascularization.	   The	   detrimental	  
effects	  of	   reduced	  renal	   function	  are	  profound	  and	  begin	  well	  before	  the	  onset	  of	  dialysis.	  
The	  overall5-­‐year	  survival	  in	  this	  cohort	  was	  43%.	  This	  is	  comparable	  to	  ours,	  namely	  42%	  in	  
patients	   with	   RAS	   after	   a	   vascular	   procedure.	   One	   may	   deduce	   from	   our	   data	   that	   the	  
increased	  mortality	   in	   the	   two	   above-­‐mentioned	   studies	   is	   due	   to	   poor	   prognostic	   impact	  
caused	  by	  incidental	  RAS.	  In	  contrast	  to	  the	  previously	  depicted	  studies,	  renal	  function	  was	  
not	   a	   prognostic	   marker	   for	   mortality	   in	   our	   cohort.	   Patients	   with	   PAD	   who	   underwent	  
vascular	  operation	  had	  better	  renal	   function	  compared	  with	  those	  who	  were	  not	  operated	  
(Table	   I).	   The	   patients	   with	   PAD	   who	   did	   not	   undergo	   vascular	   surgery	   had	   comparable	  
kidney	  function	  to	  those	  who	  underwent	  PTA	  (Table	  II).	  The	  question	  arises	  how	  this	  is	  to	  be	  
explained.	   One	   can	   hypothesize	   that	   patients	   with	   the	   worst	   renal	   function	   had	   severe	  
inoperable	   vascular	   lesions	   and	   thus	   operation	   was	   deemed	   too	   risky.	   In	   this	   respect,	  
patients	   with	   RAS	   who	   went	   through	   amputation	   had	   the	   lowest	   estimated	   glomerular	  
filtration	  rate	  (eGFR;	  60.2	  ±	  18.2	  mL/min/1.73m2).	  Another	  explanation	  may	  be	  preoperative	  
selection	   bias	   by	   the	   initial	   physicians	   who	   determined	   whether	   the	   patient	   should	   be	  
operated	   or	   not,	   based	   on	   renal	   function.	   Nevertheless,	   our	   data	   give	   us	   insight	   in	   the	  
combined	  occurrence	  of	  RAS	  and	   renal	   function	   impairment	  as	   tools	   for	  preoperative	   risk-­‐
benefit	   assessment.	   Despite	   the	   high	   mortality	   associated	   with	   incidental	   RAS	   and	   renal	  







therefore	   be	   anticipated	   that	   all	   patients	   with	   surgical	   indication	   for	   vascular	   operation	  
should	  be	  operated	  upon.	  
Some	   limitations	   of	   our	   study	   should	   be	   considered.	   Because	   this	  was	   a	   retrospective	  
post	  hoc	  analysis,	  all	   liabilities	  associated	  with	  the	  retrospective	  nature	  of	   the	  study	  apply.	  
The	   fact	   that	   90-­‐day	   postoperative	   mortality	   was	   not	   significant	   may	   be	   due	   to	  
underpowering	   of	   this	   study	   to	   really	   discriminate	   in	   short-­‐term	   mortality.	   However,	   as	  
already	  mentioned,	  the	  primary	  aim	  was	  to	  evaluate	  the	  long-­‐term	  mortality	  in	  patients	  with	  
PAD	  and	  incidental	  RAS.	  Regrettably,	  nonfatal	  perioperative	  events	  and	  medication	  use	  were	  
not	   recorded.	   The	  medication	   use	   especially	   can	   be	   of	   importance,	   since	   the	   data	   of	   this	  
study	  were	  obtained	   starting	  back	   in	   1997.	   In	   the	  past,	  many	  patients	  with	  PAD	  were	  not	  
treated	   as	   aggressively	   as	   today,	   such	   as	   standard	   with	   statins,	   angiotensin-­‐converting	  
enzyme	   inhibitors,	  or	   rigorous	  antiplatelet	   therapy.	  With	   the	  knowledge	  of	   the	  medication	  
use,	  it	  was	  possible	  to	  discriminate	  whether	  the	  patients	  in	  our	  study	  were	  treated	  according	  
to	  the	  standards	  of	  current	  practice.	  Furthermore,	  we	  cannot	  rule	  out	  that	  more	  favorable	  
patients	  were	  selected	  for	  surgery.	  
	  
CONCLUSION	  
Incidental	  RAS	  predicts	   long-­‐term	  mortality	   independent	  of	  other	   risk	   factors.	  RAS	   is	   a	  
strong	  marker	   of	   a	   poor	   prognosis,	  manifested	   in	   increased	  mortality	   and	   inoperability	   in	  
patients	   with	   PAD.	   Consequently,	   risk	   assessment	   in	   patients	   who	   undergo	   angiography	  
should	  include	  visualizing	  the	  renal	  arteries	  and	  measurement	  of	  renal	  function.	  Despite	  the	  
elevated	  mortality	   in	   subjects	  with	  RAS,	   the	  postoperative	   risk	   does	   not	   contribute	   to	   the	  
amazing	   high	   total	   mortality,	   and	   therefore	   patients	   with	   PAD	   and	   RAS	   should	   not	   be	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In	   this	   thesis	   we	   addressed	   the	   clinical	   implications	   of	   atherosclerotic	   renal	   artery	  
stenosis	   and	   the	   potential	   therapeutic	   options	   in	   patients	  with	   renovascular	   hypertension	  
and	  patients	  with	  peripheral	  arterial	  disease.	  The	  studies	  illustrate	  the	  changing	  perspective	  
on	  the	  role	  of	  the	  stenosis	  as	  such,	  that	  has	  traditionally	  been	  regarded	  as	  a	  causal	  factor	  of	  
renovascular	   hypertension,	   with	   apparently	   clear	   causal	   intervention	   possibilities	   for	  
hypertension	  and	  renal	   function.	  However,	  this	  concept	   is	   increasingly	  challenged.	  First,	  by	  
the	  variable	   results	  of	  patency	   restoration	  of	   the	   renal	  artery	  on	  blood	  pressure	  and	   renal	  
function,	   and,	   second,	   by	   the	   increasing	   recognition	   of	   the	   fact	   that	   ARAS	   is	   often	   an	  
incidental	   finding	   in	   patients	   that	   undergo	   angiography	   for	   disorders	   other	   than	  
hypertension	   such	   as	   PAD.	   Remarkably,	   presence	   of	   ARAS	   as	   an	   incidental	   finding	   has	  
substantial	   prognostic	   impact.	   So,	   in	   the	   context	   of	   incidental	   renal	   artery	   stenosis	  
“coincidental”	  is	  not	  the	  same	  as	  innocent	  in	  the	  end.	  
	  
Treatment	  of	  renovascular	  disease	  
Renal	   vascular	   intervention	   has	   historically	   played	   a	   central	   role	   in	   the	   treatment	   of	  
renovascular	  hypertension,	  based	  on	  the	  assumption	  that	  the	  renal	  artery	  stenosis	  was	  the	  
driving	  and	  maintaining	  force	  underlying	  the	  renovascular	  hypertension.	  With	  the	  technical	  
advances	  in	  endovascular	  intervention,	  even	  complex	  atherosclerotic	  lesions	  can	  be	  treated	  
in	  many	  patients.	  In	  the	  medical	  world,	  the	  enthusiasm	  for	  such	  interventions	  has	  been	  great	  
for	  a	  long	  time,	  as	  experimental	  data	  suggested	  that	  this	  was	  the	  solution	  for	  the	  Goldblatt	  
phenomenon,	  thus	  providing	  a	  causal	  therapy	  for	  renovascular	  hypertension,	  as	  a	  secondary	  
form	  of	  hypertension,	  that	  should	  therefore	  be	  the	  preferred	  treatment,	  with	  the	  theoretical	  
potential	  to	  alleviate	  the	  need	  for	  lifelong	  treatment	  with	  blood	  pressuring	  lowering	  drugs.	  
However,	  as	  we	  described	   in	  chapter	  2,	   it	  has	  become	   increasingly	  clear	   that	   the	  effect	  of	  
anatomically	  successful	  intervention	  on	  blood	  pressure	  and/	  or	  renal	  function	  is	  not	  readily	  
apparent	   for	   all	   patients.	   For	   blood	   pressure	   control,	   there	   seems	   little	   improvement	   in	  
comparison	   to	   medical	   therapy	   alone.	   As	   for	   renal	   function,	   the	   results	   are	   even	   more	  
disappointing.	  Whereas	   PTRA	   can	   favorably	   affect	   overall	   renal	   function,	   such	   an	   effect	   is	  
usually	   absent	   in	   subjects	   with	   stable	   renal	   function,	   or	   in	   those	   in	   whom	   irreversible	  
parenchymal	   damage	   is	   present,	   as	   suggested	  by	   stable	   chronic	  moderate	   to	   severe	   renal	  
function	  impairment	  or	  presence	  of	  albuminuria	  before	  intervention.	  Such	  a	  clinical	  setting	  
 






should	   therefore	   prompt	   for	   caution	   in	   decision-­‐making	   on	   renal	   vascular	   intervention.	  
Current	  data,	  including	  the	  latest	  trials,	  STAR	  [1]	  and	  ASTRAL	  [2],	  indicate	  that	  improvement	  
of	  kidney	  function	  after	  renal	  vascularization	  (on	  top	  of	  standard	  medical	  therapy)	  is	  not	  to	  
be	  expected	  for	  patients	  with	  normal	  to	  mildly	  impaired	  stable	  renal	  function,	  especially	  not	  
in	   those	   with	   unilateral	   renal	   artery	   stenosis.	   However,	   in	   selected	   cases,	   as	   shown	   by	   a	  
recent	   study	   [3],	   revascularization	   can	   result	   in	   renal	   function	   improvement,	   particular	   in	  
patients	   with	   a	   rapid	   deterioration	   of	   renal	   function	   in	   the	   year	   or	   months	   before	  
intervention,	  in	  whom	  renal	  function	  is	  nevertheless	  still	  relatively	  well	  preserved	  at	  the	  time	  
of	  intervention.	  	  
In	   the	   past	   decades,	   substantial	   progression	   has	   been	   made	   in	   the	   pharmacological	  
treatment	   of	   patients	   with	   renovascular	   hypertension.	   In	   this	   respect	   the	   introduction	   of	  
classes	   of	   antihypertensive	   medication	   blocking	   the	   renin-­‐angiotensin-­‐aldosterone	   system	  
has	   been	   of	   landmark	   importance,	   and	   the	   same	   is	   true	   for	   availability	   of	   powerful	   lipid-­‐
lowering	  drugs	  such	  as	  statins.	  By	  these	  advancements	  in	  drug	  treatment,	  it	  became	  possible	  
to	  treat	  these	  patients	  more	  aggressively,	  both	  with	  respect	  to	  blood	  pressure	  as	  such	  and	  
with	  respect	  to	  dyslipidemia	  as	  a	  factor	  driving	  progressive	  atherosclerotic	  disease.	  	  
The	  improvement	  in	  potency	  of	  pharmacological	  intervention	  may	  be	  one	  of	  the	  reasons	  for	  
lack	   of	   superiority	   of	   vascular	   intervention	   over	   conservative	   therapy.	   Restenosis,	   after	  
initially	  successful	  vascular	  intervention	  might	  be	  an	  alternative	  explanation,	  with	  potentially	  
different	  clinical	  consequences.	  No	  systematical	  assessment	  of	  the	  occurrence	  of	  restenosis	  
after	   patency	   restoration,	   and	   its	   association	   with	   responses	   of	   blood	   pressure	   and	   renal	  
function	  was	  available	  so	  far.	  Therefore,	  we	  examined	  the	  relationship	  between	  success	  of	  
angioplasty	  on	  patency	  of	   the	   renal	  artery	   (chapter	  3)	  by	  a	   systematic	  assessment	  of	  one-­‐
year	   renovascular	   patency	   after	   PTA	   irrespective	   blood	   pressure.	   Although	   the	   immediate	  
patency	  in	  our	  group	  was	  good,	  with	  96%	  patency	  in	  patients	  with	  URAS	  	  (23/24)	  and	  75%	  in	  
patients	   with	   BIRAS	   (12/16),	   after	   1	   year	   more	   than	   half	   of	   the	   patients	   (22/40)	   had	  
restenosis	  of	  their	  renal	  arteries.	  Unlike	  current	  concept,	  in	  our	  patients	  with	  unilateral	  renal	  
artery	   stenosis,	   the	   relationship	  between	   restoration	  of	   vessel	  patency	  and	  BP	   response	   is	  
not	  one-­‐to-­‐one.	  After	  1	  year,	  5	  out	  of	  10	  patients	  with	  a	  patent	  renal	  artery	  after	  PTA,	  the	  
hypertension	  returned,	  whereas	  5	  out	  of	  14	  patients	  with	  restenosis	  of	  the	  renal	  artery	  had	  
improved	   BP	   compared	   to	   baseline.	   Thus,	   taken	   together,	   in	   these	   patients	   there	  was	   no	  







bilateral	  renal	  artery	  stenosis,	  the	  results	  of	  the	  data	  are	  more	  difficult	  to	  interpret,	  because	  
in	  patients	  with	  bilateral	  lesions	  the	  elevated	  blood	  pressure	  may	  be	  maintained	  by	  either	  of	  
the	  renal	  arteries.	  Thus,	  after	  patency	  restoration	  a	  stenotic	  contralateral	  renal	  artery	  can	  be	  
the	  main	  factor	  driving	  the	  elevated	  BP.	  Since	  in	  our	  group	  of	  patients	  with	  bilateral	  stenosis,	  
a	  contralateral	  stenosis	  inaccessible	  to	  intervention	  was	  present	  in	  7	  patients,	  this	  could	  be	  
involved	  in	  the	  eventual	  BP	  effect.	  	  
Taken	  together,	  our	  findings	  support	  the	  increasing	  body	  of	  evidence	  showing	  that	  ARAS	  
is	  not	  the	  main	  pathogenetic	  factor	   in	  the	  elevated	  blood	  pressure	   in	  the	  majority	  of	  ARAS	  
patients	   with	   hypertension.	   Alleviation	   of	   the	   renal	   artery	   stenosis	   may	   be	   mainly	   a	  
“cosmetic”	  anatomical	  procedure,	  without	  affecting	  the	  true	  pathogenetic	  forces	  driving	  the	  
hypertension,	   namely	   renal	   damage	   due	   to	   ischemia	   of	   the	   stenotic	   kidney,	   resulting	   in	  
progressive	   renal	   fibrosis	   and	   atrophy	   in	   the	   post-­‐stenotic	   kidney	   accompanied	   by	  
hypertensive	  nephropathy	  in	  the	  contralateral	  kidney.	  Given	  that	  renovascular	  hypertension	  
is	  associated	  with	  activation	  of	   the	  RAAS	  as	  a	  possible	  mechanism	  underlying	   the	  elevated	  
blood	  pressure,	  we	  investigated	  in	  chapter	  4	  more	  complete	  blockade	  of	  the	  RAAS	  with	  an	  
ACE-­‐i	   and	   ARB	   dual	   blockade	   versus	   monotherapy	   on	   the	   blood	   pressure	   response	   in	  
patients	  with	  URAS.	  As	  expected,	   the	   response	  of	  blood	  pressure	  was	  equal	   in	   the	  groups	  
treated	  with	  monotherapy	  ACE-­‐i	  or	  ARB.	  The	  combined	  effect	  showed	  as	  anticipated	  further	  
decrease	   in	  blood	  pressure	   in	  absolute	  values.	  However	  with	  measurement	  of	   the	  24-­‐hour	  
blood	  pressures	  it	  did	  not	  reach	  significance	  compared	  to	  monotherapy	  alone.	  Furthermore,	  
the	   casual	   blood	   pressure	   in	   our	   patients	   was	   lower	   with	   their	   initial	   antihypertensive	  
medication	   (more	  than	  half	  of	   the	  patient	  had	  triple	   therapy)	   than	  with	  combined	  therapy	  
with	  ACE-­‐i	  and	  ARB	  –	  making	  the	  results	  difficult	  to	  interpret.	  	  
	  
 Current	  data	   indicate	   that	   improvement	  of	   kidney	   function	  after	   renal	   vascularization	  
(on	  top	  of	  standard	  medical	  therapy)	  is	  not	  to	  be	  expected	  for	  patients	  with	  normal	  to	  
mildly	   impaired	   stable	   renal	   function,	   especially	   patients	   with	   unilateral	   renal	   artery	  
stenosis.	  
 There	   is	  no	  relationship	  between	  anatomical	  effects	  on	  patency	  of	  the	  renal	  artery	  by	  
PTA,	  and	  the	  BP	  response,	  or	  recurrence	  of	  the	  stenosis	  and	  the	  return	  of	  hypertension.	  
 






 Dual	   blockade	   of	   the	   RAAS	   by	   an	   angiotensin-­‐converting-­‐enzyme	   inhibitor	   and	  
angiotensin-­‐II	   receptor	   blocker	   is	   not	   superior	   compared	   to	   either	   monotherapy	   in	  
patients	  with	  renovascular	  hypertension.	  
	  
	  
Incidental	  renal	  artery	  stenosis	  
With	  the	  emergence	  of	  angiography	  as	  a	  common	  procedure	  for	  detecting	  coronary	  as	  
well	  as	  peripheral	  arterial	  disease,	  incidental	  RAS	  is	  an	  often-­‐encountered	  condition,	  varying	  
from	  5-­‐40%.	  In	  the	  current	   literature	  the	  impact	  of	  renal	  artery	  stenosis	  as	  a	  risk	  factor	  for	  
mortality	  is	  well	  recognized,	  mainly	  based	  on	  populations	  that	  underwent	  a	  diagnostic	  work-­‐
up	   on	   clinical	   suspicion	   of	   renovascular	   hypertension.	   The	   prognostic	   impact	   of	   incidental	  
RAS	  however	  was	  not	  clear.	  	  In	  chapter	  5	  we	  demonstrated	  that	  incidental	  RAS	  is	  a	  frequent	  
finding	   (26%)	   in	   patients	   who	   are	   evaluated	   for	   PAD	   by	   DSA	   and,	   for	   the	   first	   time,	   that	  
incidental	  RAS	  predicts	  mortality	  independent	  of	  other	  well	  known	  classical	  risk	  factors,	  with	  
twofold	   mortality	   in	   RAS	   versus	   non	   RAS.	   Moreover,	   we	   found	   that	   incidental	   RAS	   was	  
closely	   associated	  with	   the	   level	   of	   renal	   function	   in	   this	   population,	  which	   allowed	   us	   to	  
look	  at	  the	  mutual	  association	  among	  renal	  artery	  stenosis,	  renal	  function	  impairment,	  and	  
mortality	  in	  patients	  with	  PAD.	  When	  renal	  artery	  stenosis	  is	  present,	  it	  is	  a	  strong	  marker	  of	  
extended	   cardiovascular	   disease	   as	   supported	   by	   the	   association	   with	   well-­‐established	  
clinical	  predictors	  of	   incidental	  RAS	  [4-­‐7].	  As	   incidental	  RAS	  emerges	  as	  a	  “byproduct”	  of	  a	  
routine	  diagnostic	  procedure,	  it	  might	  be	  useful	  to	  integrate	  this	  independent	  risk	  indicator	  
in	  the	  risk-­‐assessment	  of	  patients	  with	  PAD.	  	  
To	  be	  of	  help	   in	  clinical	  decisions,	   it	  would	  be	  useful	   to	  know	  whether	  this	  mortality	   is	  
due	   to	   an	   increased	   (peri-­‐)	   operative	   risk	   related	   to	   the	   surgical	   vascular	   procedure	   or	  
merely	   a	   representation	   of	   the	   overall	   high-­‐risk	   profile	   of	   these	   patients.	   In	   chapter	   6	  
therefore	  we	  examined	  the	  contribution	  of	  the	  peri-­‐operative	  mortality	  on	  the	  total	  (5-­‐	  and	  
10-­‐year)	  mortality.	   In	  contrast	   to	  our	  hypothesis	   the	  elevated	  mortality	  was	  not	  due	   to	  an	  
increased	   peri-­‐operative	   risk.	   The	   90	   days-­‐	   and	   1	   year	   postoperative	   mortality	   was	   not	  
significantly	   different	   in	   patients	  with	   and	   those	  without	   RAS.	   In	   terms	   of	   life	   expectancy,	  
patients	  with	   incidental	  RAS	  have	  higher	  mortality	   in	   comparison	   to	  patients	  without	  RAS,	  







Consequently,	   risk	   assessment	   in	   patients	  who	  undergo	   angiography	  with	   the	   intention	  of	  
vascular	  intervention	  should	  include	  visualizing	  the	  renal	  arteries	  and	  measurement	  of	  renal	  
function.	   This	   allows	   us	   to	   better	   identify	   the	   patients	   with	   the	   highest	   mortality	   risk,	   in	  
whom	   integrated	  vascular	   care	   (i.e.	   by	  an	   internist	  or	   cardiologist);	  with	  a	   full	  work-­‐up	   for	  
vascular	  risk	  profile	  should	  be	  prompt.	  It	  is	  known	  that	  aggressive	  treatment	  of	  hypertension	  
and	  strict	  regulation	  of	  diabetes	  improve	  cardiovascular	  morbidity	  and	  mortality	  [8-­‐13]	  and	  
that	   an	   intensive	   lipid-­‐lowering	   statin	   regimen	   can	   improve	   prognosis	   in	   high-­‐risk	  
populations	   [14-­‐17].	   Despite	   the	   elevated	   mortality	   in	   subjects	   with	   RAS,	   the	   peri-­‐	   and	  
postoperative	   risk	   does	   not	   contribute	   to	   the	   strikingly	   high	   total	  mortality	   and	   therefore	  
patients	  with	   PAD	  and	   renal	   artery	   stenosis	   should	  not	   be	  withheld	   from	  vascular	   surgery	  
when	  indicated.	  	  
 Patients	  with	  peripheral	  arterial	  disease	  and	  incidental	  renal	  artery	  stenosis	  have	  a	  high	  
mortality	  rate	  compared	  to	  those	  without	  renal	  artery	  stenosis.	  
 Incidental	  renal	  artery	  stenosis	   is	  a	   frequent	  finding	   in	  patients	  who	  are	  evaluated	  for	  
peripheral	   arterial	   disease	   by	  DSA,	   and	   this	   finding	   predicts	  mortality	   independent	   of	  
other	  risk	  factors.	  
 The	  elevated	  mortality	   in	  patients	  with	  peripheral	  arterial	  disease	  and	  incidental	  renal	  
artery	   stenosis	   is	   not	   due	   to	   a	   higher	   postoperative	   risk.	   Subjects	   presenting	   with	  
peripheral	   arterial	   disease	   and	   renal	   artery	   stenosis	   can	   therefore	   undergo	   vascular	  
procedures	  with	  the	  same	  risk	  as	  other	  patients.	  
	  
	  
From	  Goldblatt	  phenomenon	  to	  generalized	  vascular	  disease:	  the	  changing	  perspective	  of	  
atherosclerotic	  renal	  artery	  stenosis.	  
From	  the	  first	  reports	  by	  Harry	  Goldblatt	   in	  1934	  [18]	  until	   to	  date,	  researchers	  have	  
tried	   to	   find	   the	   “holy	   grail”	   for	   the	   treatment	   of	   renovascular	   hypertension.	   At	   first	   this	  
seemed	   very	   straightforward,	   since	   obstruction	   of	   the	   renal	   artery	   is	   the	   cause	   of	   the	  
hypertension,	   and	   accordingly	   relief	   of	   the	   stenosis	   by	   renal	   artery	   intervention	   could	  
alleviate	   the	   stenosis,	   keep	   the	   artery	   patent	   and	   consequently	   cure	   the	   hypertension.	   As	  
such,	  renovascular	  hypertension	  has	  long	  been	  in	  the	  textbooks	  as	  one	  of	  the	  main	  forms	  of	  
secondary	  hypertension,	  for	  which	  a	  causal	  treatment	  was	  available.	  Now,	  decades	  later	  and	  
facing	   the	   outcome	   of	   the	   recent	   STAR	   [1]	   and	   ASTRAL	   [2]	   trials,	   we	   have	   come	   to	   the	  
 






conclusion	  that	  the	  reality	   is	  more	  complex	  than	  in	  the	  first	  reports	  described	  by	  Goldblatt	  
and	  colleagues,	  and	  that	  restoration	  of	  renal	  artery	  patency	  not	  always	  leads	  to	  a	  persisted	  
reduction	  of	  blood	  pressure	  or	  improvement	  of	  renal	  function.	  
To	  understand	  the	  discrepancy	  between	  the	  Goldblatt	  phenomenon	  and	  the	  frequent	  
lack	  of	  success	  in	  patients	  with	  ARAS,	  two	  important	  mechanisms	  should	  be	  considered.	  The	  
first	   one	   is	   the	   potential	   of	   reduced	   renal	   perfusion	   pressure	   to	   induce	   a	   rise	   in	   systemic	  
blood	  pressure	  by	  renin	  release	  and	  the	  consequent	  activation	  of	  angiotensin	  II.	  The	  ensuing	  
cascade	   includes	   sympathetic	   nerve	   activation	   and	   recruitment	   of	   endothelium-­‐based	  
proliferation	  systems,	  only	  some	  of	  which	  are	  reversible	  upon	  restoring	  renal	  perfusion	  [19].	  
Inflammatory	   and	   pro-­‐fibrogenic	   pathways	   become	   activated	   during	   sustained	   renal	  
ischemia	   and	   perpetuate	   irreversible	   renal	   damage.	   These	   factors	   often	   lead	   to	   tubulo-­‐
interstitial	  scarring	  and	  loss	  of	  glomerular	  filtration	  over	  time.	  In	  this	  phase,	  restoring	  renal	  
artery	   perfusion	   usually	   no	   longer	   induces	   meaningful	   recovery	   of	   function	   since	   the	  
impairment	  of	  renal	  function	  in	  this	  stage	  reflects	   late,	  structural	  effects	  of	  sustained	  renal	  
ischemia,	   rather	   than	   a	   reversible	   hemodynamic	   impairment.	   Second,	   it	   is	   important	   to	  
realize	   that	   atherosclerotic	   narrowing	   of	   the	   renal	   artery	   is	   usually	   not	   an	   isolated	  
phenomenon,	   but	   part	   of	   a	   progressive	   process	   of	   generalized	   atherosclerosis.	   This	   is	  
supported	   by	   multiple	   observations	   where	   ARAS	   is	   found	   together	   with	   coronary	   artery	  
disease	   [5,	   20],	   carotid	   artery	   stenosis	   [21,	   22]	   and	   in	   patients	   with	   peripheral	   arterial	  
disease	   [23-­‐25].	  As	  discussed	   in	  chapter	  5	  and	  6	  of	   this	   thesis,	   incidental	  RAS	   is	  associated	  
with	   increased	   prevalence	   of	   well-­‐established	   risk	   factors	   such	   as	   diabetes	   mellitus,	  
hypertension,	   coronary	   and	   cerebrovascular	   disease.	   Hence,	   the	   presence	   of	   renal	   artery	  
stenosis	   is	   a	   strong	  marker	   of	   extended	   generalized	   atherosclerotic	   cardiovascular	   disease	  
and	   the	   increased	  mortality	   found	   in	   these	  patients	   reflects	   their	   extensive	   cardiovascular	  
burden.	   	   Consequently,	   revascularization	   of	   the	   ARAS	   alone	   will	   not	   alter	   the	   risk	   of	  
cardiovascular	  morbidity	  and	  mortality.	  	  	  
So	  where	  do	  we	  go	  from	  here?	  It	  must	  be	  concluded	  that	  the	  Goldblatt	  phenomenon,	  
which	   is	   one	   of	   the	   most	   studied	   models	   of	   hypertension,	   holds	   true	   for	   patients	   with	  
fibromuscular	  disease,	  where	  alleviation	  of	  the	  renal	  artery	  stenosis,	  in	  an	  otherwise	  healthy	  
vascular	   bed,	   cures	   the	   hypertension.	   In	   patients	  with	   ARAS,	   this	   is	   only	   true	   for	   selected	  
cases	   and	   the	   most	   consistent	   predictor	   of	   benefit	   regarding	   both	   blood	   pressure	   and	  







diagnosis	  and	  revascularization	  [3,	  26-­‐28]	  that	  can	  be	  taken	  as	  a	  clinical	  indicator	  of	  the	  (lack	  
of)	   chronicity	   of	   the	   post-­‐stenotic	   renal	   damage.	   For	   that	   reason,	   our	   primary	   focus	   in	  
patients	   encountered	   with	   ARAS	   is	   optimal	   treatment	   of	   generalized	   atherosclerosis	  
according	  to	  the	  current	  guidelines.	   In	  addition,	  and	  not	  yet	  based	  on	  guidelines,	  currently	  
new	   treatment	  modalities	   are	   being	   developed	   such	   as	   catheter-­‐based	   renal	   denervation,	  
which	  has	  shown	  its	  effectiveness	  in	  patients	  with	  treatment-­‐resistant	  hypertension	  [29,	  30].	  
As	  already	  mentioned,	  sympathetic	  nerve	  activation	  plays	  an	  important	  role	  in	  the	  rise	  and	  
maintaining	   of	   elevated	   systemic	   blood	   pressure	   in	   patients	   with	   ARAS.	   Currently,	   this	  
relatively	   new	   technique	   has	   only	   been	   applied	   in	   “normal”	   renal	   arteries.	   One	   can	  
hypothesize	   to	   combine	   the	   dilatation	   or	   stenting	   of	   the	   renal	   artery	   stenosis	   with	   renal	  
denervation	   in	   the	   contralateral	   kidney	   to	   ensure	   optimal	   treatment	   of	   the	   hypertension.	  
Apart	   from	  all	   this,	   the	  greatest	   challenge	  at	   this	  moment	   remains	   to	   select	   the	   individual	  
patient	  who	  is	  likely	  to	  benefit	  from	  renal	  artery	  revascularization.	  	  
To	  date,	  most	  imaging	  procedures	  concentrate	  specifically	  upon	  the	  anatomic	  severity	  
and	   approachability	   of	   the	  ARAS,	  whereas	   functional	   characterization,	   such	   as	   renography	  
with/without	  ACE-­‐i,	  and	  renal	  vein	  catheterization	  has	  largely	  been	  abandoned	  due	  to	  lack	  of	  
predictive	  power.	  While	  the	  anatomical	  characteristics	  are	  important,	  they	  are	  evidently	  not	  
sufficient	   to	   predict	   the	   outcome	   of	   renal	   revascularization.	   Further	   work	   is	   needed	   to	  
develop	  diagnostic	  tools	  that	  can	  identify	  renal	  parenchyma	  at	  true	  risk	  of	  “ischemic	  injury”	  
and	   to	   identify	   when	   kidney	   function	   can	   be	   (or	   can	   no	   longer	   be)	   improved	   with	   renal	  
revascularization.	  Until	  then,	  clinicians	  face	  the	  important	  task	  to	  weigh	  the	  pros	  and	  cons	  of	  
renal	   artery	   intervention	   in	   the	   context	   of	   the	   available	   evidence	   each	   time	   ARAS	   is	  
encountered	  in	  the	  individual	  patient.	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   In	   dit	   proefschrift	   wordt	   de	   klinische	   betekenis	   onderzocht	   van	   atherosclerotisch	   nier	  
arterie	   stenose	   (ARAS)	   en	   de	   eventuele	   behandel	   mogelijkheden	   bij	   patiënten	   met	  
renovasculaire	  hypertensie	  en	  perifeer	  arterieel	  vaatlijden	  (PAV).	  De	  studies	  laten	  zien	  dat	  de	  
rol	   van	   nier	   arterie	   stenose,	   dat	   van	  
oudsher	   wordt	   beschouwd	   als	   oorzaak	  
(causale	   factor)	   van	   renovasculaire	  
hypertensie	   met	   een	   duidelijk	  
aangrijpingspunt	   voor	   behandeling	   aan	  
het	  veranderen	  is.	  Aan	  dit	  concept	  wordt	  
namelijk	  steeds	  meer	  getwijfeld.	  
In	   de	   eerste	   plaats	   door	   de	   wisselende	  
resultaten	   van	   het	   dotteren	   van	   de	   nier	  
arterie	   stenose	   op	   de	   bloeddruk	   en	  
nierfunctie.	   Anderzijds	   doordat	   steeds	  
vaker	   bij	   toeval	   (incidenteel)	   een	   nier	  
arterie	  stenose	  wordt	  gevonden	  bij	  patiënten	  die	  een	  angiografie	  ondergaan	  in	  verband	  met	  
perifeer	   vaatlijden.	   Opmerkelijk	   is	   dat	   deze	   bij	   toeval	   gevonden	   nier	   arterie	   stenose,	   een	  
voorspellende	  waarde	  heeft	  op	  de	  overleving	  van	  patiënten.	  Derhalve	  betekent	  incidenteel	  
nier	  arterie	  stenose	  niet	  altijd	  dat	  het	  onschuldig	  is.	  
	  
In	  hoofdstuk	  2	  worden	  de	  onderzoeken	  beschreven	  die	  tot	  nu	  toe	  zijn	  uitgevoerd	  naar	  
het	  effect	  van	  dotteren	  van	  de	  nier	  arterie	  stenose	  op	  de	  bloeddruk	  en	  nierfunctie.	  Uit	  de	  
onderzoeksresultaten	  komt	  naar	  voren	  dat	  het	  effect	  op	  verbetering	  van	  de	  bloeddruk	  klein	  
is,	  ondanks	  een	  succesvolle	  dotter	  procedure.	  Verbetering	  van	  de	  nierfunctie	  na	  het	  (beter)	  
doorgankelijk	   maken	   van	   de	   nier	   arterie	   (boven	   op	   standaard	   medicatie)	   wordt	   niet	  
verwacht	  bij	   patiënten	  met	  normale	   tot	  matig	  gestoorde	  nierfunctie.	  Dit	   geldt	   vooral	   voor	  
patiënten	  met	  enkelzijdige	  nier	  arterie	  stenose.	  	  
	  
Atherosclerotisch	  nier	  arterie	  stenose	  (ARAS)	  
=	   vernauwing	   van	   de	   nierslagader	   door	  
aderverkalking.	  
Renovasculaire	   hypertensie	   =	   hoge	  
bloeddruk	   	   en	   vermindering	   van	   nierfunctie	  
veroorzaakt	   door	   vernauwing	   van	   de	  
nierslagader.	  
Perifeer	   arterieel	   vaatlijden	   (PAV)	   =	  
vernauwing	   van	   de	   bloedvaten	   in	   de	   benen	  
wat	   vaak	   gepaard	   gaat	  met	   pijn	   tijdens	   het	  
lopen;	   in	  volksmond	  ook	  wel	  “etalage	  benen	  
genoemd”.	  
Dotteren=	  open	  maken	  of	  wijder	  maken	  van	  
een	   bloedvat	   door	  middel	   van	   het	  opblazen	  
van	  een	  ballon	  in	  het	  bloedvat.	  









In	   hoofdstuk	   3	   wordt	   gekeken	   waarom	   het	   bloeddruk	  
verlagend	   effect	   na	   een	   dotter	   procedure	   tegenvalt.	   We	  
hebben	  dit	  gedaan	  door	  de	  relatie	  te	  onderzoeken	  tussen	  een	  
succesvolle	   dotter	   ingreep	   en	   de	   patency	   van	   de	   nierarterie.	  
Hoewel	   de	   onmiddellijke	   patency	   goed	  was	   (90	  %),	   had	   na	   1	  
jaar	  meer	  dan	  de	  helft	  van	  de	  patiënten	  bewezen	  opnieuw	  een	  stenose.	  Tevens	  	  konden	  we	  
geen	  relatie	  vinden	  tussen	  de	  bloeddruk	  respons	  na	  1	  maand,	  na	  1	  jaar	  en	  de	  patency	  van	  de	  
nier	   arterie.	  Met	   andere	   woorden,	   patiënten	   die	   geen	   nier	   arterie	   stenose	  meer	   hadden,	  
hadden	  soms	  weer	  een	  hoge	  bloeddruk	  en	  vice	  versa.	  	  
	  
	   In	   hoofdstuk	   4	   wordt	   bij	   patiënten	   met	   een	  
enkelzijdige	   nier	   arterie	   stenose,	   het	   bloeddruk	  
verlagend	   effect	   vergeleken	   van	   2	   medicijnen	  
afzonderlijk	   (enalapril	   en	   losartan)	   versus	   de	  
combinatie	  van	  beide.	  De	  gebruikte	  medicijnen	  zorgen	  
voor	   bloeddruk	   daling	   door	   een	   remmende	   werking	   op	   het	   renine-­‐angiotensinesysteem.	  
Beide	  medicijnen	  alleen	  gaven	  hetzelfde	  bloeddruk	  dalend	  effect,	  de	  combinatie	  gaf	  nog	  een	  
verdere	   daling,	   echter	   was	   dit	   niet	   belangrijkverschillend	   tijdens	   de	   24-­‐uurs	   bloeddruk	  
registratie.	  	  
	  
Hoofdstuk	   5	   beschrijft	   de	   resultaten	   van	   550	   patiënten	   met	   PAV	   die	   een	   angiografie	  
hebben	  ondergaan.	  Incidentele	  nier	  arterie	  stenose	  met	  een	  vernauwing	  van	  meer	  dan	  50%	  
kwam	   in	  26%	  van	  de	   gevallen	   voor.	   Sterfte	   in	  de	   groep	  met	  nier	   arterie	   stenose	  was	  59%	  
vergeleken	  met	  28%	  in	  de	  groep	  zonder	  nier	  arterie	  stenose.	  De	  traditionele	  risico	  factoren	  
voor	  hart	  en	  vaat	  ziekten	  kwamen	  tevens	  vaker	  voor	  bij	  patiënten	  met	  nier	  arterie	  stenose.	  
Incidentele	   nier	   arterie	   stenose	   was	   een	   onafhankelijke	   voorspeller	   voor	   sterfte,	   net	   als	  
leeftijd,	  suikerziekte,	  roken	  en	  patiënten	  die	  een	  hartinfarct	  dan	  wel	  hersenberoerte	  hebben	  
gehad.	  
	  
In	   hoofdstuk	   6	   wordt	   tot	   slot	   de	   bijdrage	   van	   sterfte	   rond	   de	   operatieperiode	   op	   de	  
lange-­‐termijn	  sterfte	  onderzocht	  (5-­‐	  en	  10-­‐jaarssterfte)	  in	  patiënten	  met	  PAV	  en	  nier	  arterie	  
stenose.	   De	   sterfte	   was	   vergelijkbaar	   voor	   patiënten	   die	   een	   vaatoperatie	   hebben	  
Patency	  =	  mate	  van	  
geopend:	  meer	  dan	  
70%	  vernauwing	  is	  
ernstig	  en	  minder	  dan	  
50	  %	  vernauwing	  is	  
niet	  belangrijk.	  
renine-­‐angiotensinesysteem:	  
hormoon	  systeem	  wat	  in	  de	  
nier	  geactiveerd	  wordt	  bij	  
patiënten	  met	  een	  nier	  arterie	  
stenose	  en	  zorgt	  voor	  







ondergaan	  (54.5%)	  vergeleken	  met	  patiënten	  die	  niet	  werden	  geopereerd	  (49.6%).	  Er	  was	  90	  
dagen	  na	  de	  operatie	  geen	  verschil	  in	  sterfte	  tussen	  de	  patiënten	  zonder	  en	  met	  nier	  arterie	  
stenose.	  Wel	  hadden	  de	  patiënten	  met	  nier	  arterie	  stenose	  die	  geopereerd	  waren	  significant	  
hogere	   lange-­‐termijn	   sterfte	   (65.1%)	   vergeleken	   met	   patiënten	   zonder	   een	   nier	   arterie	  
stenose	   (43.5%).	   Leeftijd	   was	   de	   enige	   voorspeller	   voor	   sterfte	   90	   dagen	   na	   de	   operatie.	  
Zoals	  verwacht	  was	  incidentele	  nier	  arterie	  stenose	  wel	  een	  onafhankelijke	  voorspeller	  voor	  





Met	  het	  schrijven	  van	  dit	  dankwoord	  komt	  er	  een	  einde	  aan	  een	  "project"	  dat	  ongeveer	  10	  
jaar	  geleden	  in	  Almelo	  begon.	  Ik	  probeer	  in	  chronologische	  volgorde	  iedereen	  te	  bedanken	  
die	  hebben	  bijgedragen	  aan	  dit	  boekje	  (met	  eten	  als	  rode	  draad).	  
	  
Allereerst	   kwam	   ik	   als	   student	  met	  de	  nefrologie	   in	   aanraking	  door	  onderzoek	   te	  doen	  bij	  	  	  
dr.	   W.J.	   van	   Son	   en	   dr.	   W.W.	   Bakker.	   Beste	   Willem,	   door	   jouw	   altijd	   onafgebroken	  
enthousiasme	  voor	  zowel	  kliniek	  als	  onderzoek,	  wist	  ik	  dat	  ik	  nefroloog	  wilde	  worden.	  Wat	  ik	  
nog	  altijd	  niet	  vergeten	  ben	  is	  ons	  gezamenlijke	  etentje	  in	  de	  haven	  van	  San	  Francisco	  (vlak	  
na	   9/11)	   met	   de	   lekkerste	   krab	   en	   kreeft	   die	   Charlotte	   en	   ik	   ooit	   hebben	   gehad!	   Beste	  
Winston,	   bedankt	   voor	   jouw	  wetenschappelijke	   onderwijs,	   onze	   gezamenlijke	   artikelen	   en	  
meerdere	   poster	   presentaties.	   Zeker	   onvergetelijk	   was	   de	   heerlijke	   Indische	   rijsttafel	   bij	  
jouw	  thuis.	  	  
	  
Als	  co-­‐assistent	  kwam	  ik	  wederom	  in	  aanraking	  met	  de	  nefrologie	  door	  m’n	  co-­‐schappen	  te	  
lopen	  in	  het	  AZG	  op	  afdeling	  D4.	  Onder	  de	  begeleiding	  van	  dr.	  R.T.	  Gansevoort	  kreeg	  ik	  als	  
tip	   m'n	   keuze	   co-­‐schap	   te	   lopen	   in	   Almelo	   (dacht	   toen	   wel	   eventjes:	   "waar	   ligt	   dat	   nou	  
weer?").	  Beste	  Ron,	  bedankt	  voor	  deze	  gouden	  tip.	  Zie	  wat	  er	  uit	  voort	  gekomen	  is.	  
In	  Almelo	  ben	  ik	  dus	  beland	  waar	  ik	  mijn	  opleider,	  Dr.	  L	  van	  Bergeijk	  ontmoette.	  Beste	  Leo,	  
hartelijk	   dank	   voor	   jouw	   steun	   en	   vertrouwen.	   Door	   jou	   mocht	   ik	   als	   keuze	   co	   meteen	  
doorstromen	  als	  AGNIO	  interne	  en	  later	  kwam	  ik	  al	  snel	  in	  opleiding	  tot	  internist.	  	  
Als	  beginnend	  assistent	  heb	  je	  natuurlijk	  goede	  voorbeelden	  nodig	  op	  de	  werkvloer	  (bedankt	  
Margo	  Themmen)	  om	  te	  leren	  wat	  je	  wel	  en	  niet	  moet	  doen	  in	  acute	  situaties.....	  
Beste	   Mengalvio,	   als	   paranimf	   heb	   je	   niet	   alleen	   letterlijk	   bijgedragen	   aan	   dit	   boekje,	  
waarvoor	  ik	  jou	  wil	  bedanken,	  maar	  ook	  jouw	  bewonderenswaardige	  rust	  die	  je	  uitstraalt	  in	  
acute	  medische	  situaties,	  heeft	  veel	   indruk	  op	  me	  gemaakt.	   Ik	  weet	  nog	  heel	  goed	  mijn	  1e	  
astma	  cardiale	  patiënt	  op	  de	  CCU	  als	  arts	  assistent.	  Nerveus	  dat	  ik	  was,	  niet	  wetende	  wat	  ik	  
allemaal	  moest	  doen,	  zei	   je:	  "het	  komt	  goed,	   'n	  beetje	  lasix,	   'n	  beetje	  morfine	  en	  heel	  veel	  
zuurstof".	   Onze	   gezamenlijke	   passie	   voor	   eten	   (lees	   noodles)	   hoop	   ik	   nog	   lang	   met	   je	   te	  
mogen	  delen!	  
Als	  arts	  assistent	   in	  Almelo,	  ontkom	  je	  er	  niet	  aan	  om	  geen	  onderzoek	  te	  doen,	  of	  het	  nou	  




uitgevoerd	   onder	   de	   bezielende	   begeleiding	   van	   dr.	   A.J.J.	   Woittiez.	   Beste	   Arend	   Jan,	   als	  
copromotor,	  heeft	  dit	  boekje	  het	  licht	  niet	  kunnen	  zien	  zonder	  jou.	  Met	  nier	  arterie	  stenose	  
als	  jouw	  kindje,	  is	  het	  kindje	  uiteindelijk	  geboren	  (wel	  iets	  langere	  draagtijd	  dan	  verwacht).	  
Onze	   tripjes	   naar	   het	   Noorden	   en	   onze	   meerdere	   diner	   besprekingen	   (Denver	   Colorado,	  
Zwolle)	  waren	  allen	  zeer	  geslaagd	  en	  hebben	  uiteindelijk	  geleid	  tot	  dit	  resultaat!	  	  
De	  afdeling	  radiologie	  en	  chirurgie	  van	  het	  Twenteborg	  ziekenhuis	  wil	   ik	  bedanken	  voor	  de	  
samenwerking.	  Zonder	  die	  samenwerking	  was	  het	  niet	  gelukt.	  
	  
Alvorens	  ik	  terug	  ging	  naar	  Groningen	  voor	  m'n	  vervolgopleiding	  interne	  werd	  ik	  voorgesteld	  
aan	   Prof.	   dr.	   G.J.	   Navis.	   Beste	   Gerjan,	   als	   mijn	   promotor	   wil	   ik	   mijn	   grote	   bewondering	  
uitspreken	  over	  de	  wijze	  waarop	  jij	  naar	  de	  wetenschap	  kijkt.	  De	  passie	  en	  het	  vermogen	  om	  
dingen	  beter	  te	  maken	  en	  te	  begrijpen	  door	  er	  over	  "te	  praten	  en	  te	   filosoferen"	  heeft	  dit	  
boekje	   gemaakt	   tot	  wat	   het	   nu	   is	   geworden.	  Het	   slijpen	   van	   de	   tekst	   (wat	   soms	   door	  mij	  
werd	  aangeleverd	  als	  ruwe	  diamant	  ;-­‐)	  tot	  iets	  moois	  kan	  jij	  als	  geen	  ander,	  getuige	  de	  mooie	  
artikelen	  die	  we	  hebben	  gepubliceerd,	  wat	  zelfs	  werd	  aangehaald	  in	  This	  Month’s	  Highlights	  
van	  de	  JASN	  (17:	  1757-­‐1758).	  
	  
Eenmaal	   in	  Groningen	  wil	   ik	  mijn	  opleiders	  Prof.	  dr.	  R.O.B.	  Gans	  (Interne	  Geneeskunde)	  en	  
Prof.	  dr.	  P.E.	  de	  Jong	  (Nefrologie)	  bedanken	  voor	  de	  genoten	  opleiding.	  	  
	  
Prof.	  dr.	  C.J.A.M.	  Zeebregts,	  beste	  Clark,	  wil	  ik	  bedanken	  voor	  het	  meedenken	  en	  de	  hulp	  bij	  
hoofdstuk	  6	  en	  de	  bereidheid	   tot	  deelname	   in	  de	   leescommissie.	  Onze	  eerste	  ontmoeting	  
tijdens	   een	   borrel	   in	   Almelo	   was	   erg	   gezellig.	   Je	   had	   toen	   al	   voorgesteld	   om	   samen	   een	  
stukje	  te	  schrijven.	  
	  
Prof.	  dr.	  C.A.J.M.	  Gaillard	  en	  Prof.	  dr.	  W.P.Th.M.	  Mali	  wil	   ik	  bedanken	  voor	  het	  beoordelen	  
van	  het	  manuscript.	  	  
	  
Mijn	   maten	   in	   Harderwijk	   wil	   ik	   bedanken	   voor	   hun	   belangstelling	   en	   bemoedigende	  







Zonder	   familie	  was	  dit	  boekje	  er	  nooit	  geweest.	  Mijn	  ouders	  wil	   ik	  bedanken	  voor	  het	   feit	  
dat	  ik	  hier	  ben	  en	  zo	  ver	  heb	  kunnen	  komen	  en	  hun	  geloof	  in	  mij.	  	  
Mijn	  "tai	  koe	  ma"	   (大	  姑	  媽)	  en	  mijn	  overleden	  oma	  (嬤嬤)	  en	   familie	   in	  Hong	  Kong	  wil	   ik	  
bedanken	  voor	  de	  liefdevolle	  opvoeding	  en	  het	  feit	  dat	  ze	  er	  voor	  mij	  waren	  geweest.	  	  
M’n	  broertje,	  a.k.a.	  Andruin	  Mui	  a.k.a.	  paranimf	  wil	  ik	  bedanken	  voor	  de	  fantastische	  lay-­‐out	  
van	  dit	  boekje.	  Hopelijk	  volgt	  binnenkort	  jouw	  1e	  roman!	  	  
Jesper	  (bedankt	  妹妹	  voor	  zo'n	  leuke	  妹	  夫)	  wil	  ik	  bedanken	  voor	  de	  statistische	  analyse	  in	  
hoofdstuk	  3.	  Hopelijk	  wordt	  jouw	  dag	  net	  zo	  mooi.	  
	  
Mijn	  overleden	  opa	  en	  oma	  Scholten:	   ik	  weet	  dat	   ze	  erg	  blij	   voor	  mij	   zouden	  zijn	  geweest	  
met	  deze	  dag!	  Voor	  mij	  waren	  jullie	  net	  m’n	  eigen	  Opa	  en	  Oma,	  altijd	  geïnteresseerd	  in	  wat	  
ik	  deed	  en	  hoe	  het	  in	  het	  ziekenhuis	  was.	  Dank	  dat	  jullie	  er	  voor	  mij	  zijn	  geweest!	  	  
Mijn	   lieve	   schoonouders,	   Jur	   en	   Christien,	   vanaf	   het	   1e	  moment	  werd	   ik	   liefdevol	   in	   jullie	  
familie	  opgenomen.	  Gelukkig	  kende	   ik	  Joost	  al	  goed,	  anders	  had	   ik	  de	  ballotage	  commissie	  
misschien	  niet	  overleefd	  ;-­‐)	  Ik	  hoop	  dat	  jullie	  nog	  vele	  jaren	  met	  ons	  kunnen	  genieten.	  
	  
Tot	   slot:	   de	  belangrijkste	  persoon	   in	  m’n	   leven.	   Lieve,	   lieve	   leneu,	   dank	   voor	   je	   geduld	  en	  
zorgzaamheid	  (broodjes	  smeren)	  en	   je	  weet	  hoeveel	   ik	  van	   je	  hou.	  Samen	  met	   jou	  hoop	  ik	  

















List	  of	  abbreviations	  
	  
ACE-­‐i:	  angiotensin	  –converting-­‐enzyme	  inhibitors	  	  
ARAS:	  atherosclerotic	  renal	  artery	  stenosis	  
ARB:	  angiotensin-­‐II	  receptor	  blockers	  	  
ASTRAL	  trial:	  Angioplasty	  and	  STent	  for	  Renal	  Artery	  Lesions	  
BIRAS:	  bilateral	  renal	  artery	  stenosis	  
BP:	  blood	  pressure	  
CORAL	  trial:	  Cardiovascular	  Outcomes	  in	  Renal	  Atherosclerotic	  Lesions	  
DRASTIC	  trial:	  Dutch	  Renal	  Artery	  Stenosis	  Intervention	  Cooperative	  
DSA:	  digital	  subtraction	  angiography	  
EMMA	  trial:	  Essai	  Multicentrique	  Medicaments	  vs	  Angioplastie	  
FMD:	  fibromuscular	  dysplasia	  
GFR:	  glomerular	  filtration	  rate	  
MDRD:	  Modification	  of	  Diet	  in	  Renal	  Disease	  
NITER:	  Nephropathy	  Ischemic	  Therapy	  
NS:	  not	  significant	  
PAD:	  peripheral	  arterial	  disease	  
PTRA:	  percutaneous	  transluminal	  renal	  angioplasty	  	  	  
PTRAS:	  percutaneous	  transluminal	  renal	  angioplasty	  plus	  stenting	  
PVD:	  peripheral	  vascular	  disease	  
RAAS:	  renin-­‐angiotensin-­‐aldosterone	  system	  
RAS:	  renal	  artery	  stenosis	  
SNRASCG—Scottish	  and	  Newcastle	  Renal	  Artery	  Stenosis	  Collaborative	  Group	  
STAR	  trial:	  STent	  placement	  in	  patients	  with	  Atherosclerotic	  Renal	  Artery	  
Stenosis	  and	  Impaired	  Renal	  Function	  
URAS:	  unilateral	  renal	  artery	  stenosis	  
	  
	  
	  
	  
	  
